documents incorporated reference document part proxy statement annual meeting shareholders held may part iii filed securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data afinancial statements notes consolidated financial statements report independent registered public accounting firm bsupplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities sales vaccines major european markets marketed companys sanofi pasteur msd joint venture termination december beginning merck record vaccine sales european markets previously part joint venture company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients mercks alliances segment primarily includes results companys relationship astrazeneca lp termination relationship june october company divested consumer care segment developed manufactured marketed overthecounter foot care sun care products company incorporated new jersey financial information information companys segments see item managements discussion analysis financial condition results operations item financial statements supplementary data product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners product sales total company sales including sales companys top pharmaceutical products well total sales animal health products follows millions total sales pharmaceutical januviajanumet zetiavytorin gardasilgardasil proquadmmr iivarivax keytruda isentress remicade cubicin singulair pneumovax animal health consumer care revenues october company divested consumer care segment developed manufactured marketed overthecounter foot care sun care products revenues primarily comprised miscellaneous corporate revenues including revenue hedging activities thirdparty manufacturing sales table contents pharmaceutical companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders certain products within companys franchises follows primary care womens health cardiovascular zetia ezetimibe marketed ezetrol countries outside united states vytorin ezetimibesimvastatin marketed inegy outside united states atozet ezetimibe atorvastatin marketed certain countries outside united states cholesterol modifying medicines diabetes januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes general medicine womens health nuvaring etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshaped subdermal contraceptive implant dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate combination medicine treatment asthma follistim aq follitropin beta injection marketed puregon countries outside united states fertility treatment hospital specialty hepatitis zepatier elbasvir grazoprevir treatment adult patients chronic hepatitis c virus hcv genotype gt gt infection ribavirin certain patient populations pegintron peginterferon alphab victrelis boceprevir medicines treatment chronic hcv hiv isentress raltegravir hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection hospital acute care cubicin daptomycin injection iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms noxafil posaconazole prevention invasive fungal infections invanz ertapenem sodium treatment certain infections cancidas caspofungin acetate antifungal product bridion sugammadex injection medication reversal two types neuromuscular blocking agents used surgery primaxin imipenem cilastatin sodium antibacterial product immunology remicade infliximab treatment inflammatory diseases simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases company markets europe russia turkey oncology keytruda pembrolizumab treatment previously untreated metastatic nonsmallcell lung cancer nsclc patients whose tumors express high levels pdl tumor proportion score tps previously treated metastatic nsclc patients whose tumors express pdl tps well advanced melanoma previously treated recurrent metastatic head neck cancer emend aprepitant prevention chemotherapy induced postoperative nausea vomiting temodar temozolomide marketed temodal outside united states treatment certain types brain tumors diversified brands respiratory singulair montelukast medicine indicated chronic treatment asthma relief symptoms allergic rhinitis nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptoms cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatments hypertension arcoxia etoricoxib treatment arthritis pain company markets outside united states fosamax alendronate sodium marketed fosamac japan treatment prevention osteoporosis zocor simvastatin statin modifying cholesterol table contents vaccines gardasil human papillomavirus quadrivalent types vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccines help prevent certain diseases caused certain types human papillomavirus hpv proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella zostavax zoster vaccine live vaccine help prevent shingles herpes zoster rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease animal health animal health segment discovers develops manufactures markets animal health products including vaccines principal products segment include livestock products nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorders cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiencies beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type killed baculovirus vector vaccine lines infectious diseases swine poultry products nobilisinnovax live mareks disease vector vaccine lines poultry paracox coccivac coccidiosis vaccines companion animal products bravecto fluralaner line products kills fleas ticks dogs weeks nobivac vaccine lines flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabetes mellitus treatment dogs cats panacur fenbendazolesafeguard fenbendazole broadspectrum anthelmintic dewormer use many animals regumate altrenogest fertility management horses prestige vaccine line horses activyl indoxacrbscalibor deltamethrinexspot protecting bites fleas ticks mosquitoes sandflies aquaculture products slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor florfenicol antibiotic farmraised fish discussion sales companys products see item managements discussion analysis financial condition results operations product approvals january merck announced us food drug administration fda approved zepatier treatment adult patients chronic hcv gt gt infection ribavirin certain patient populations february merck announced fda approved supplemental new drug application singledose emend injection prevention delayed nausea vomiting adults receiving initial repeat courses moderately emetogenic chemotherapy may company received marketing approval european medicines agency ema bravecto spoton solution cats dogs july company received approval united states market product tradename bravecto topical table contents july european commission ec approved zepatier oncedaily single tablet combination therapy treatment chronic hcv gt gt infection ribavirin certain patient populations august merck announced fda approved keytruda treatment patients recurrent metastatic head neck cancer disease progression platinumcontaining chemotherapy october merck announced fda approved keytruda firstline treatment patients nsclc whose tumors high pdl expression tps determined fdaapproved test egfr alk genomic tumor aberrations addition october merck announced fda approved zinplava injection mgml zinplava indicated reduce recurrence clostridium difficile infection cdi patients years age older receiving antibacterial drug treatment cdi high risk cdi recurrence january merck announced ec approved keytruda firstline treatment metastatic nsclc adults whose tumors high pdl expression tps egfr alk positive tumor mutations joint ventures sanofi pasteur msd december merck sanofi pasteur sanofi terminated equallyowned joint venture formed companies develop market human vaccines europe licenses subsidiary scheringplough corporation scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company marketing rights products throughout europe russia turkey remicade lost market exclusivity major european markets february company longer market exclusivity marketing territories company continues market exclusivity simponi marketing territories profits derived mercks distribution two products countries equally divided merck jj competition health care environment competition markets company conducts business pharmaceutical industry general highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug manufacturers animal health care companies companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent rights increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result payment royalties recognition impairment charge respect intangible assets associated certain products competitive pressures intensified pressures industry grown pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company well positioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances licensing arrangements refining sales marketing efforts address table contents changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors health care environment government regulation global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities hospitals serving disproportionate share low income uninsured patients backdrop united states enacted major health care reform legislation patient protection affordable care act aca began implemented various insurance market reforms advanced state federal insurance exchanges launched respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole approximately million million million recorded merck reduction revenue respectively related donut hole provision also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion increase billion fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid company recorded million million million costs within marketing administrative expenses respectively annual health care reform fee higher expenses reflect final regulations annual health care reform fee issued internal revenue service irs july final irs regulations accelerated recognition criteria fee obligation one year year underlying sales used allocate fee occurred rather year fee paid result change merck recorded additional year expense million february centers medicare medicaid services cms issued medicaid rebate final rule implements provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs impact changes resulting issuance rule material merck time however company still awaiting guidance cms two aspects rule deferred later implementation include definition constitutes product line extension delay participation us territories medicaid drug rebate program april company evaluate financial impact two elements become effective significant uncertainty future aca particular healthcare laws general united states company participating debate monitoring proposed changes could affect business company unable predict likelihood changes aca depending nature repeal replacement aca actions could material adverse effect companys results operations financial condition business also vermont legislature passed pharmaceutical cost transparency law law requires manufacturers identified vermont green mountain care board report certain product price information vermont attorney general attorney general required submit report legislature number states introduced legislation kind company expects states continue focus pharmaceutical price transparency extent proposals pass law unknown time company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states table contents include practices managed care organizations federal state exchanges institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures example health care reform contributing increase number patients medicaid program sales pharmaceutical products subject substantial rebates addition effort contain us federal deficit pharmaceutical industry could considered potential source savings via legislative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls medicare prescription drug program part addition congress may consider proposals allow certain conditions importation medicines countries remains uncertain proposals may included part future federal budget deficit reduction proposals would directly indirectly affect company us private sector consolidation integration among healthcare providers major factor competitive marketplace pharmaceutical products health plans pharmacy benefit managers consolidating fewer larger entities thus enhancing purchasing strength importance private thirdparty insurers well governments increasingly employ formularies control costs negotiating discounted prices exchange formulary inclusion failure obtain timely adequate pricing formulary placement mercks products obtaining pricing placement unfavorable pricing could adversely impact revenue addition formulary tier copay differentials private health insurance companies selfinsured employers raising copayments required beneficiaries particularly branded pharmaceuticals biotechnology products private health insurance companies also increasingly imposing utilization management tools clinical protocols requiring prior authorization branded product generic product available requiring patient first fail one generic products permitting access branded medicine utilization management tools also used treatment areas payer taken position multiple branded products therapeutically comparable us payer market concentrates drugs become available generic form pharmaceutical companies may face greater pricing pressure private thirdparty payers order provide information companys pricing practices company recently posted website first pricing action transparency report united states years report provides companys average annual list price net price increases across companys us portfolio dating back report shows companys average annual net price increases taking sales deductions rebates discounts returns account across us human health portfolio low midsingle digits since additionally weighted average annual discount rate steadily increasing time reflecting competitive market branded medicines impact aca companys gross us sales reduced result rebates discounts returns efforts toward health care cost containment also remain intense european countries company faces competitive pricing pressure resulting generic biosimilar drugs addition majority countries europe attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs brand authorities use price data markets set new local prices brandname drugs including companys guidelines examining reference pricing usually set local markets changed pursuant local regulations addition japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines occurred furthermore government order repricings classes drugs determines appropriate applicable rules certain markets outside united states also implemented cost management strategies health technology assessments hta require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement united states htas also used government private payers companys focus emerging markets continued governments many emerging markets also focused constraining health care costs enacted price controls related measures compulsory table contents licenses aim put pressure price pharmaceuticals constrain market access company anticipates pricing pressures market access challenges continue varying degrees emerging markets beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability significant currency fluctuation controls financial crises limited changing availability funding health care developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces pharmaceutical industry also subject regulation regional country state local agencies around world focused standards processes determining drug safety effectiveness well conditions sale reimbursement particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements practices increased amount time resources necessary develop new products bring market united states time fda committed expediting development review products bearing breakthrough therapy designation accelerated regulatory review process medicines designation european union eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment see research development discussion regulatory approval process access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging include set principles company strives embed operations business strategies guide companys worldwide approach expanding access health care addition company many farreaching philanthropic programs merck patient assistance program provides medicines adult vaccines free people united states prescription drug health insurance coverage without companys assistance afford merck medicine vaccines merck launched merck mothers longterm effort global health partners end preventable deaths complications pregnancy childbirth merck also provided funds merck foundation independent organization partnered variety organizations dedicated improving global health table contents privacy data protection company subject significant number privacy data protection laws regulations globally many place restrictions companys ability transfer access use personal data across business legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including new eu general data protection regulation become effective impose penalties global revenue additional laws regulations enacted united states europe asia latin america increased enforcement litigation activity united states developed markets increased regulatory cooperation among privacy authorities globally company adopted comprehensive global privacy program manage evolving risks certified compliant approved asia pacific economic cooperation crossborder privacy rules system euus privacy shield program binding corporate rules eu distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business patents trademarks licenses patent protection considered aggregate material importance companys marketing products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant current us patent law provides additional patent term periods patented product regulatory review fda eu also provides additional six months pediatric market exclusivity attached products supplementary protection certificate spc japan provides additional term pediatric studies attached market exclusivity unrelated patent rights table contents patent portfolios developed products introduced company normally provide market exclusivity company following key patent protection united states eu japan including potential patent term extensions pte spcs indicated following marketed products product year expiration us year expiration eu year expiration japan invanz composition na arcoxia marketed marketed cancidas formulation zostavax expired use na dulera formulation na na combination zetia vytorin asmanex formulation formulation formulation nuvaring delivery system delivery system na emend injection follistim aq formulation formulation formulation noxafil na rotateq expired expired recombivax method making expired expired januvia janumet na janumet xr na na isentress simponi na na bridion pending pte nexplanon device device marketed bravecto pending pte patent spcs gardasil gardasil patent spcs na keytruda patent spcs pending pte zerbaxa pending pte patent spcs na sivextro patent spcs na zinplava pending pte na belsomra na zepatier patent spcs na currently marketing approval note compound patent unless otherwise noted certain products listed may subject patent litigation see item financial statements supplementary data note contingencies environmental liabilities eu date represents expiration date following five countries france germany italy spain uk major eu markets spc granted major eu markets patent expiry date spc expiry date listed agreement generic manufacturer launched generic version zetia united states december august district court decision found invalid companys patent claiming nuvarings delivery system decision currently appeal eligible months pediatric exclusivity pte system japan allows patent extended provided later approval directed different indication previous approval may result multiple pte approvals given patent expiration date company marketing rights us japan spc applications filed july expected expiry eligible pediatric exclusivity expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries table contents additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties company following key us patent protection drug candidates review united states fda additional patent term may provided pipeline candidates based patent term restoration pediatric exclusivity currently anticipated review us year expiration us v pediatric hexavalent combination vaccine method making company also following key us patent protection drug candidates phase development currently anticipated phase drug candidate year expiration us v ebola vaccine mk letermovir mk anacetrapib mka relebactam imipenemcilastatin mk verubecestat mk doravirine mk ertuglifozin mka ertuglifozin sitagliptin mkb ertuglifozin metformin mk vericiguat unless otherwise noted patents charts compound patents patent subject future patent term restoration five years six month pediatric market exclusivity either may available addition depending circumstances surrounding final regulatory approval compound may listed patents patent applications pending could relevance product finally approved relevance application would depend upon claims ultimately may granted nature final regulatory approval product also regulatory exclusivity tied protection clinical data complementary patent protection cases may provide effective longer lasting marketing exclusivity compounds patent estate united states data protection generally runs five years first marketing approval new chemical entity extended seven years orphan drug indication years first marketing approval biological product information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities research development expenses billion billion billion included restructuring costs acquisition divestiturerelated costs years company prioritizes research development efforts focuses candidates believes represent breakthrough science make difference patients payers table contents company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed making externally sourced programs greater component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies company also reviews pipeline examine candidates may provide value outlicensing company continues evaluate certain latestage clinical development platform technology assets determine outlicensing sale potential companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases neurodegenerative diseases respiratory diseases development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included new drug application nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologic believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness situations clinical program incorporates adaptive design methodology use accumulating data decide modify aspects ongoing clinical study continues without undermining validity integrity trial one type adaptive clinical trial adaptive phase ab trial design twostage trial design consisting phase proofofconcept stage phase b doseoptimization finding stage data phase trials satisfactory company commences largescale phase trials confirm compounds efficacy safety another type adaptive clinical trial adaptive phase trial design study includes interim analysis adaptation changes trial features common phase study eg multiple dose groups design similar phase trial adaptive phase trial design reduces timelines eliminating activities would required start separate study upon completion phase trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase studies doseranging studies finally phase trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies united states fda review process begins complete nda bla submitted received accepted review agency within days receipt fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted table contents priority review standard review pursuant prescription drug user fee act v pdufa fda review period target ndas original blas either six months priority review ten months standard review time application deemed sufficiently complete review timelines determined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing complete response letter crl stating application approved present form describing deficiencies fda identified company wish pursue application receiving crl resubmit application information addresses questions issues identified fda order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission fda four program designations fast track breakthrough therapy accelerated approval priority review facilitate expedite development review new drugs address unmet medical needs treatment serious lifethreatening conditions fast track designation provides pharmaceutical manufacturers opportunities frequent interactions fda reviewers products development ability manufacturer rolling submission ndabla rolling submission allows completed portions application submitted reviewed fda ongoing basis breakthrough therapy designation provides manufacturers features fast track designation well intensive guidance implementing efficient development program product commitment fda involve senior managers experienced staff review accelerated approval designation allows fda approve product based effect surrogate intermediate endpoint reasonably likely predict products clinical benefit generally requires manufacturer conduct required postapproval confirmatory trials verify clinical benefit priority review designation means fdas goal take action ndabla within six months compared ten months standard review addition generating antibiotic incentives act fda may grant qualified infectious disease product qidp status antibacterial antifungal drugs intended treat serious life threatening infections including caused antibiotic antifungal resistant pathogens novel emerging infectious pathogens qualifying pathogens qidp designation offers certain incentives development qualifying drugs including priority review nda filed eligibility fast track designation fiveyear extension applicable exclusivity provisions food drug cosmetic act primary method company uses obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states outside united states eu company submits marketing applications national regulatory authorities examples pharmaceuticals medical devices agency japan health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia china food drug administration country separate independent review process timeline many markets approval times longer regulatory authority requires approval major market united states eu issuance certificate pharmaceutical product market initiating local review process table contents research development update company currently several candidates regulatory review united states keytruda fdaapproved antipd programmed death receptor therapy clinical development expanded indications different cancer types keytruda currently approved treatment nsclc melanoma advanced melanoma head neck cancer february fda accepted review two supplemental blas sbla keytruda patients locally advanced metastatic urothelial cancer including bladder cancers application firstline use granted priority review treatment patients ineligible cisplatincontaining therapy application secondline use granted priority review patients disease progression platinum containing chemotherapy pdufa action date applications june fda previously granted breakthrough therapy designation keytruda secondline treatment patients locally advanced metastatic urothelial cancer disease progression platinumcontaining chemotherapy january fda accepted review sbla keytruda plus chemotherapy pemetrexed plus carboplatin firstline treatment patients metastatic advanced nonsquamous nsclc regardless pdl expression egfr alk genomic tumor aberrations first application regulatory approval keytruda combination another treatment fda granted priority review pdufa action date may sbla reviewed fdas accelerated approval program december fda accepted review sbla keytruda treatment patients refractory classical hodgkin lymphoma patients relapsed three prior lines therapy fda granted priority review pdufa action date march sbla reviewed fdas accelerated approval program november fda accepted review sbla keytruda treatment previously treated patients advanced microsatellite instabilityhigh msih cancer fda granted priority review pdufa action date march sbla reviewed fdas accelerated approval program fda recently granted breakthrough therapy designation keytruda unresectable metastatic msih noncolorectal cancer previously granted treatment patients unresectable metastatic msih colorectal cancer additionally keytruda also received breakthrough therapy designation fda treatment patients primary mediastinal bcell lymphoma refractory relapsed two prior lines therapy keytruda clinical development program consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including bladder colorectal esophageal gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma multiple myeloma nasopharyngeal nsclc ovarian prostate renal triplenegative breast many currently phase clinical development trials planned cancers mk investigational followon biologic insulin glargine candidate treatment patients type type diabetes review fda mk approved eu january mk developed collaboration partially funded samsung bioepis v investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda developed approved commercialized partnership merck sanofi vaccine designed help protect six important diseases diphtheria tetanus pertussis whooping cough polio poliovirus types invasive disease caused haemophilus influenzae type b hib hepatitis b november fda issued crl respect bla v companies reviewing crl plan communication fda february ec granted marketing authorization v prophylaxis diphtheria tetanus pertussis hepatitis b poliomyelitis invasive disease caused hib infants toddlers age weeks v marketed vaxelis eu addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed table contents mk verubecestat investigational small molecule inhibitor betasite amyloid precursor protein cleaving enzyme bace treatment alzheimers disease february merck announced external data monitoring committee edmc recommended termination phase epoch study verubecestat mildtomoderate alzheimers disease based low probability success study edmc recommended separate phase study apecs evaluating verubecestat amnestic mild cognitive impairment due alzheimers disease also known prodromal alzheimers disease continue planned estimated primary completion date apecs study fully enrolled february mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raising hdlc reducing ldl c anacetrapib evaluated patient eventdriven cardiovascular clinical outcomes trial sponsored oxford university reveal randomized evaluation effects anacetrapib lipidmodification involving patients preexisting vascular disease november merck announced data monitoring committee dmc reveal outcomes study completed planned review unblinded study data recommended study continue changes dmc reviewed safety efficacy data study included assessment futility merck remains blinded actual results analysis reveal safety efficacy data study last patients last visit occurred january company anticipates receiving topline results study midyear mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approved carbapenem antibiotic fda designated combination qidp designated fast track status treatment hospitalacquired bacterial pneumonia ventilatorassociated bacterial pneumonia complicated intraabdominal infections complicated urinary tract infections mk letermovir investigational oral oncedaily intravenous infusion antiviral candidate prevention clinicallysignificant cytomegalovirus cmv infection letermovir received orphan drug status eu united states also granted fast track designation october merck announced pivotal phase clinical study letermovir met primary endpoint global multicenter randomized placebocontrolled study evaluated efficacy safety letermovir adult years older cmvseropositive recipients allogeneic hematopoietic stem cell transplant merck plans submit regulatory applications approval letermovir united states eu mk ertugliflozin investigational oral sglt inhibitor evaluated treatment type diabetes collaboration pfizer inc pfizer september merck pfizer announced phase study vertis sita ertugliflozin met primary endpoint mg mg daily doses ertugliflozin showed significantly greater reductions ac average measure blood glucose past two three months added patients background sitagliptin metformin ertugliflozin also studied combination januvia sitagliptin metformin december merck submitted ndas fda ertugliflozin two fixeddose combinations mka ertugliflozin plus januvia mkb ertugliflozin plus metformin company anticipates response fda first quarter ertugliflozin two fixeddose combinations currently review eu mkj investigational fixeddose combination sitagliptin ipragliflozin development commercialization japan collaboration astellas pharma inc astellas ipragliflozin sglt inhibitor codeveloped astellas kotobuki pharmaceutical co ltd kotobuki approved use japan copromoted merck kotobuki v investigational rvsvzebov ebola vaccine candidate studied large scale phase clinical trials november merck newlink genetics announced exclusive licensing collaboration agreement investigational ebola vaccine december merck announced application emergency use assessment listing eual v accepted review world health organization according eual process designed expedite availability vaccines needed public health emergencies another outbreak ebola decision grant v eual status based data regarding quality safety efficacyeffectiveness well riskbenefit analysis emergency use eual designation allows emergency use vaccine remains investigational yet licensed commercial distribution july merck announced fda granted v breakthrough therapy designation ema granted vaccine candidate prime priority medicines status december end study results ring vaccination trial reported lancet supporting july interim assessment table contents v offers substantial protection ebola virus disease reported cases among vaccinated individuals days vaccination randomized nonrandomized clusters results ongoing studies anticipated second half mk vericiguat investigational treatment heart failure studied phase clinical trial patients suffering chronic heart failure development vericiguat part worldwide strategic collaboration merck bayer ag v inactivated varicella zoster virus vzv vaccine development prevention herpes zoster company completed phase trial autologous hematopoietic cell transplant patients conducting another phase trial patients solid tumor malignancies undergoing chemotherapy hematological malignancies study autologous hematopoietic cell transplant patients met primary endpoints merck presented results study american society blood marrow transplantation meetings february mk doravirine investigational nonnucleoside reverse transcriptase inhibitor developed merck treatment hiv infection february company received positive results first phase study showing doravirine noninferior alternative regimen achieving maintaining hiv suppression infected adults weeks treatment company also divested discontinued certain drug candidates merck announced discontinuing development odanacatib investigational cathepsin k inhibitor osteoporosis seek regulatory approval use merck previously reported numeric imbalance adjudicated stroke events pivotal phase fracture outcomes study postmenopausal women company decided discontinue development independent adjudication analysis major adverse cardiovascular events confirmed increased risk stroke company determined business reasons would terminate north america partnership agreement alkabell included mk investigational allergy immunotherapy tablet house dust mite allergy merck given alkabell six months notice terminating agreement therefore compound returned alkabell decision due efficacy safety concerns company also decided business reasons discontinue clinical development mkb referred next generation ring investigational combination etonogestrel estradiol vaginal ring contraception treatment dysmenorrhea women seeking contraception decision due efficacy safety concerns merck announced business reasons proceed submitting marketing applications omarigliptin investigational onceweekly dpp inhibitor united states europe decision result concerns efficacy safety omarigliptin table contents chart reflects companys research pipeline february candidates shown phase include specific products date candidate entered phase development candidates shown phase include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations except otherwise noted candidates phase additional indications therapeutic area respect keytruda additional claims line extensions formulations inline products shown phase phase phase entry date review asthma alzheimers disease new molecular entitiesvaccines mk mk verubecestat december allergy cancer atherosclerosis mk house dust mite us mk keytruda mk anacetrapib may diabetes mellitus pmbcl primary mediastinal bacterial infection mk us large bcell lymphoma mka relebactamimipenemcilastatin mk ertugliflozin eu advanced solid tumors october mka ertugliflozinsitagliptin eu nasopharyngeal cancer mkb ertugliflozinmetformin eu ovarian mk keytruda pediatric hexavalent combination vaccine prostate bladder october eu v us mk breast october cough including cough ipf colorectal november certain supplemental filings mk esophageal december cancer diabetes mellitus gastric may keytruda mk head neck november eu previously treated microsatellite instabilityhigh cancer us hepatitis c hepatocellular may relapsed refractory classical hodgkin lymphoma us mkb mk uprifosbuvirmk hodgkin lymphoma july eu combination chemotherapy firstline nonsquamous nonsmall grazoprevirmk ruzasvir multiple myeloma december cell lung cancer us pneumoconjugate vaccine renal october first line cisineligible bladder cancer us v cmv prophylaxis transplant patients second line metastatic bladder cancer us mk letermovir june diabetes mellitus mk ertugliflozin november footnotes us developed collaboration mka ertugliflozinsitagliptin mk developed part north america partnership september us alkabell merck given alkabell six months notice mkb ertugliflozinmetformin terminating agreement therefore compound august us returned alkabell mkj sitagliptinipragliflozin october japan v investigational pediatric hexavalent combination vaccine dtap ebola vaccine ipvhibhepb developed approved v march commercialized partnership merck sanofi november heart failure fda issued crl respect v companies mk vericiguat september reviewing crl plan communication fda herpes zoster v inactivated vzv vaccine december hiv mk doravirine december employees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups restructuring activities company incurs substantial costs restructuring program activities related mercks productivity cost reduction initiatives well connection integration certain acquired businesses company commenced actions global restructuring programs designed streamline cost structure actions programs include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company also continues reduce global real estate footprint improve efficiency manufacturing supply network nonfacility related restructuring actions programs substantially complete remaining activities primarily relate ongoing facility rationalizations since inception programs december merck eliminated approximately positions comprised table contents employee separations well elimination contractors vacant positions company expects substantially complete remaining actions programs end environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying accruing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial position results operations liquidity capital resources year merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy water use greenhouse gas emissions company believe risks material business time geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states percentage total company sales sales sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions merck operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas companys business provided item financial statements supplementary data available information companys internet website address wwwmerckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished us securities exchange commission sec addition company provide without charge copy annual report including financial statements schedules upon written request shareholder merck shareholder services merck co inc galloping hill road k kenilworth nj usa companys corporate governance guidelines charters board directors four standing committees available companys website wwwmerckcomaboutleadership information available print stockholder requests company table contents item risk factors investors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents claims third parties infringement company company defends patents within outside united states including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated ndas fda seeking market generic forms companys products prior expiration relevant patents owned licensed company company normally responds defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases thirdparty patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies circumstances could diminish eliminate sales profits regions negatively affect companys results operations court decisions relating companies patents potential legislation relating patents well regulatory initiatives may result general weakening intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available case certain products loss could result material noncash impairment charge companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products chart listing patent protection certain companys marketed products us patent protection candidates review phase candidates set forth item business patents trademarks licenses companys products lose market exclusivity company generally experiences significant rapid loss sales products company depends upon patents provide exclusive marketing rights products period time loss patent protection one companys products typically leads significant rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss market exclusivity material adverse effect companys business cash flow results operations financial position prospects example pursuant table contents agreement generic manufacturer manufacturer launched united states generic version zetia december addition company lose us patent protection vytorin april company expects significant rapid loss sales zetia vytorin united states key products generate significant amount companys profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows companys ability generate profits operating cash flow depends largely upon continued profitability companys key products januvia janumet keytruda gardasilgardasil isentress zepatier result companys dependence key products event adversely affects products markets products could significant adverse impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects results postapproval trials increased competition introduction new effective treatments discontinuation removal market product reason events could material adverse effect sales products companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products year expected declines sales products loss market exclusivity mean companys future success dependent pipeline new products including new products may develop joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research development process new drugs result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results competing products manufacturers may reach market first clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved regulators intended use may possible obtain patent new drug payers may refuse cover reimburse new product sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects table contents companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market fail succeed numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection acquisitions failure successfully develop market new products short term long term would material adverse effect companys business results operations cash flow financial position prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including eu united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval including results postapproval phase trials studies may decrease demand companys products including following rereview products already marketed recall loss marketing approval products already marketed table contents changing government standards public expectations regarding safety efficacy labeling changes greater scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pharmaceutical medical device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities company faces intense competition lower costgeneric products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states eu political pressure reduce spending prescription drugs led legislation measures encourages use generic biosimilar products although companys policy actively protect patent rights generic challenges companys products arise time companys patents may prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial position prospects company faces intense competition competitors products addition factors could certain circumstances lead noncash impairment charges companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective convenient use effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial position prospects addition products measured fair value capitalized connection acquisitions experience difficulties market negatively impact product cash flows company may recognize material non cash impairment charges respect value products table contents company faces pricing pressure respect products company faces increasing pricing pressure globally particularly mature markets managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca iii state activities aimed increasing price transparency changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition us larger customers may future ask receive higher rebates drugs certain highly competitive categories company must also compete placed formularies managed care organizations exclusion product formulary lead reduced usage managed care organization order provide information companys pricing practices company recently posted website first pricing action transparency report united states years report provides companys average annual list price net price increases across companys us portfolio dating back report shows companys average annual net price increases taking sales deductions rebates discounts returns account across us human health portfolio low midsingle digits since additionally weighted average annual discount rate steadily increasing time reflecting competitive market branded medicines impact aca companys gross us sales reduced result rebates discounts returns outside united states numerous major markets including eu japan pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products company expects pricing pressures increase future health care industry united states continue subject increasing regulation political action company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered congress state legislatures united states enacted major health care reform legislation form aca various insurance market reforms advanced state federal insurance exchanges launched respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion increase billion fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid january centers medicare medicaid services cms issued medicaid rebate final rule implements provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs impact changes resulting issuance rule material merck time however company still awaiting guidance cms two aspects rule deferred later implementation include definition constitutes product line extension delay participation us territories medicaid drug rebate program april company evaluate financial impact two elements become effective table contents company predict likelihood future changes health care industry general pharmaceutical industry particular impact may companys results operations financial condition business changes laws regulations could materially adversely affect companys business aspects companys business including research development manufacturing marketing pricing sales litigation intellectual property rights subject extensive legislation regulation changes applicable federal state laws agency regulations could material adverse effect companys business particular significant uncertainty future aca healthcare laws general united states company participating debate monitoring proposed changes could affect business company unable predict likelihood changes aca depending nature repeal replacement aca actions could material adverse effect companys results operations financial condition business uncertainty global economic conditions together austerity measures taken certain governments could negatively affect companys operating results uncertainty global economic conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial position prospects global efforts toward health care cost containment continue exert pressure product pricing market access many international markets governmentmandated pricing actions reduced prices generic patented drugs addition austerity measures negatively affected companys revenue performance company anticipates pricing actions austerity measures continue negatively affect revenue performance credit economic conditions worsen resulting economic currency impacts affected markets globally could material adverse effect companys results company significant global operations expose additional risks adverse event could material negative impact companys results operations extent companys operations outside united states significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease table contents failure attract retain highly qualified personnel could affect ability successfully develop commercialize products companys success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry intense company sure able attract retain quality personnel costs materially increase past company experienced difficulties delays manufacturing certain products merck past experienced difficulties manufacturing certain vaccines products company may future experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii construction delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply manufacturing difficulties result product shortages leading lost sales reputational harm company company may able realize expected benefits investments emerging markets company taking steps increase sales emerging markets however guarantee companys efforts expand sales markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets addition many countries currencies fluctuate substantially currencies devalue company offset devaluations companys financial performance within countries could adversely affected addition china commercial economic conditions may adversely affect companys growth prospects market company continues believe china represents important growth opportunity events coupled heightened scrutiny health care industry may continue impact product pricing market access generally company anticipates reported inquiries made various governmental authorities involving multinational pharmaceutical companies china may continue reasons sales within emerging markets carry significant risks however failure maintain companys presence emerging markets could material adverse effect business financial condition results companys operations company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter acquisition licensing borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates could negatively affect companys results operations financial position cash flows occurred respect venezuela order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options forwards interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful table contents company subject evolving complex tax laws may result additional liabilities may affect results operations company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued addition company may affected changes tax laws including tax rate changes changes laws related remittance foreign earnings deferral limitations impacting us tax treatment foreign earnings new tax laws revised tax law interpretations domestic foreign jurisdictions pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions reliance third party relationships outsourcing arrangements could adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies third party service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business company increasingly dependent sophisticated software applications computing infrastructure company increasingly dependent sophisticated software applications computing infrastructure conduct critical operations disruption degradation manipulation applications systems intentional accidental means could impact key business processes cyberattacks companys applications systems could result exposure confidential information modification critical data andor failure critical operations misuse applications systems could result disclosure sensitive personal information theft trade secrets confidential business information company continues leverage new innovative technologies across enterprise improve efficacy efficiency business processes use create new risks although aggregate impact companys operations financial condition material date company target events nature expects continue company monitors data information technology personnel usage company systems reduce risks continues ongoing basis current potential threats assurance companys efforts protect data systems prevent service interruption loss critical sensitive information companys companys third party providers databases systems could result financial legal business reputational harm company negative events animal health industry could negative impact future results operations future sales key animal health products could adversely affected number risk factors including certain risks specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy mad cow disease could lead widespread death precautionary destruction well reduced consumption demand animals could adversely impact companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt production vaccines sites force company incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include table contents epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant biologics carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics particularly human animal health vaccines long expensive uncertain process unique risks uncertainties biologics including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions united states eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval required release manufactured commercial lot manufacturing biologics especially large quantities often complex may require use innovative technologies handle living micro organisms lot approved biologic must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics frequently costly manufacture production ingredients derived living animal plant material biologics made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead allegations harm including infections allergic reactions closure product facilities due possible contamination events could result substantial costs product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost increased significantly respect product liability company selfinsures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise social media platforms present risks challenges inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments company table contents social networking web site could damage companys reputation brand image goodwill disclosure nonpublic companysensitive information companys workforce others external media channels could lead information loss although internal company social media policy guides employees appropriate personal professional use social media company processes place may completely secure protect information identifying new points entry social media continues expand also presents new challenges cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forward looking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic andor biosimilar products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities table contents increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters located kenilworth new jersey companys us commercial operations headquartered upper gwynedd pennsylvania companys us pharmaceutical business conducted divisional headquarters located upper gwynedd pennsylvania kenilworth new jersey companys vaccines business conducted divisional headquarters located west point pennsylvania mercks animal health global headquarters located madison new jersey principal us research facilities located rahway kenilworth new jersey west point pennsylvania palo alto california boston massachusetts elkhorn nebraska animal health principal research facilities outside united states located switzerland china mercks manufacturing operations headquartered whitehouse station new jersey company also production facilities human health products nine locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties japan singapore south africa countries western europe central south america asia capital expenditures billion billion billion united states amounted billion million million abroad expenditures amounted million million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company believes properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference item financial statements supplementary data note contingencies environmental liabilities item mine safety disclosures applicable table contents executive officers registrant ages february officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board name age offices business experience chairman president chief executive officer since december president chief executive kenneth c frazier officer january december president may january adele ambrose senior vice president chief communications officer since november executive vice president president merck manufacturing division since march senior sanat chattopadhyay vice president operations merck manufacturing division november march executive vice president global services chief financial officer since april executive vice president chief financial officer april april corporate vice president robert davis president medical products baxter international inc march richard r deluca jr executive vice president president merck animal health since september executive vice president chief patient officer strategic communications global public policy population health since july executive vice president strategic communications global public policy population health january july president merck vaccines julie l gerberding january january mirian graddickweir executive vice president human resources since november executive vice president general counsel since july executive vice president chief ethics compliance officer june july executive vice president general counsel michael j holston board secretary hewlettpackard company december senior vice president finance global controller since march assistant controller november rita karachun march executive vice president president merck research laboratories since april executive roger perlmutter md phd vice president research development amgen inc february adam h schechter executive vice president president global human health since may table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk common stock market price information set forth table based historical nyse market prices following table also sets forth calendar periods indicated dividend per share information cash dividends paid per common share year th q rd q nd q st q common stock market prices th q rd q nd q st q high low high low january approximately shareholders record issuer purchases equity securities three months ended december follows issuer purchases equity securities millions total number average price approximate dollar value shares shares paid per may yet purchased period purchased share plans programs october october november november december december total shares purchased period made part plan approved board directors march purchase billion merck shares shares approximated table contents performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major usbased pharmaceutical companies abbvie inc bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp compound annual growth rate peer group average calculated market cap weighted basis addition abbvie inc replaced abbott laboratories peer group beginning following spin abbott laboratories performance graph deemed incorporated reference filing securities act securities exchange act except extent company specifically incorporates reference addition performance graph deemed soliciting material filed sec subject regulation c provided regulation sk liabilities section securities exchange act except extent company specifically requests information treated soliciting material specifically incorporates reference filing securities act exchange act table contents item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report merck co inc subsidiaries millions except per share amounts results year sales materials production marketing administrative research development restructuring costs income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders cash dividends declared cash dividends declared per common share capital expenditures depreciation average common shares outstanding millions average common shares outstanding assuming dilution millions yearend position working capital property plant equipment net total assets longterm debt total equity yearend statistics number stockholders record number employees amounts include charge related settlement worldwide patent litigation related keytruda amounts include net charge related settlement vioxx shareholder class action litigation foreign exchange losses related venezuela gains dispositions businesses assets favorable benefit certain tax items amounts reflect divestiture mercks consumer care business october including gain sale well gain recognized option exercise astrazeneca gains dispositions businesses assets loss extinguishment debt amounts include net charge recorded connection settlement certain shareholder litigation amounts restated give effect adoption accounting guidance issued financial accounting standards board see note item financial statements table contents item managements discussion analysis financial condition results operations description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities sales vaccines major european markets marketed companys sanofi pasteur msd spmsd joint venture termination december beginning merck record vaccine sales european markets previously part joint venture company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients mercks alliances segment primarily includes results companys relationship astrazeneca lp termination relationship june october company divested consumer care segment developed manufactured marketed overthecounter foot care sun care products overview merck continued execute innovation strategy companys sustained investment research yielded number recent approvals regulatory milestones across various therapeutic areas company received several approvals include expanded indications keytruda companys antipd programmed death receptor therapy approved us food drug administration fda firstline treatment metastatic nonsmallcell lung cancer nsclc well treatment head neck cancer additionally fda european commission ec approved zepatier oncedaily single tablet combination therapy treatment chronic hepatitis c virus hcv genotype gt gt infection ribavirin certain patient populations worldwide sales billion increase compared including unfavorable effect foreign exchange sales growth driven oncology hcv vaccine hospital acute care products reflecting part ongoing launches keytruda zepatier bridion well positive performance mercks animal health business growth areas largely offset effects generic biosimilar competition resulted declines products remicade nasonex business development remains important component companys overall strategy merck seeks identify best external innovation augment portfolio pipeline particular focus earlytomidstage pipeline assets merck looks growth opportunities meet companys strategic criteria looking best scientific opportunities merck remains financially disciplined pursuing business opportunities company believes contribute longterm growth sustainable value shareholders january merck acquired iomet pharma ltd iomet drug discovery company focused development innovative medicines treatment cancer particular emphasis fields cancer immunotherapy cancer metabolism july merck acquired afferent pharmaceuticals afferent privately held pharmaceutical company focused development therapeutic candidates targeting px receptor treatment common poorlymanaged neurogenic conditions chronic cough addition merck entered strategic collaboration license agreement moderna therapeutics moderna develop commercialize novel messenger rna mrnabased personalized cancer vaccines table contents merck continues support inline portfolio well ongoing upcoming product launches keytruda launching around world multiple indications merck achieved multiple additional regulatory milestones keytruda including approval fda firstline treatment patients nsclc whose tumors high pdl expression tumor proportion score tps determined fdaapproved test egfr alk genomic tumor aberrations also treatment patients recurrent metastatic head neck squamous cell carcinoma disease progression platinumcontaining chemotherapy additionally ec approved keytruda treatment locally advanced metastatic nsclc patients whose tumors express pdl received least one prior chemotherapy regimen january ec approved keytruda firstline treatment metastatic nsclc adults whose tumors high pdl expression tps egfr alk positive tumor mutations additionally company continuing launch zepatier united states emerging markets launching european union eu japan merck focusing research efforts therapeutic areas believes impact human health oncology diabetes cardiometabolic disease resistant microbial infection alzheimers disease addition recent regulatory approvals discussed company continued advance programs latestage pipeline several regulatory submissions merck five supplemental biologics license applications sbla priority review fda keytruda including use combination chemotherapy firstline treatment patients metastatic advanced nonsquamous nsclc regardless pdl expression egfr alk genomic tumor aberrations treatment patients classical hodgkin lymphoma treatment previously treated patients advanced microsatellite instabilityhigh cancer firstline treatment patients locally advanced metastatic urothelial cancer including bladder cancers secondline treatment patients locally advanced metastatic urothelial cancer disease progression platinumcontaining chemotherapy merck driving broad immunooncology development program investing longterm potential keytruda become foundational treatment range cancers keytruda clinical development program includes clinical trials tumor types trials combine keytruda cancer treatments mk insulin glargine candidate treatment patients type type diabetes developed collaboration also review fda addition phase programs keytruda therapeutic areas breast colorectal esophageal gastric hepatocellular multiple myeloma renal cancers company also candidates phase clinical development several therapeutic areas see research development past year company continued focus productivity improvements looking opportunities reallocate resources across portfolio grow strongest brands support promising assets pipeline marketing administrative expenses declined compared reflecting part continued focus company prioritizing resources highest growth areas research development expenses reflect increased clinical development spending company continues invest pipeline november mercks board directors raised companys quarterly dividend per share per share company returned billion shareholders dividends share repurchases january merck entered settlement license agreement resolve worldwide patent infringement litigation related keytruda connection settlement merck recorded pretax charge million fourth quarter see note consolidated financial statements earnings per common share assuming dilution attributable common shareholders eps compared eps years reflect impact acquisition divestiturerelated costs including charge related uprifosbuvir clinical development program well restructuring costs certain items nongaap eps excludes items see nongaap income non gaap eps table contents operating results sales worldwide sales billion increase compared foreign exchange unfavorably affected global sales performance includes lower benefit revenue hedging activities compared revenue growth primarily reflects higher sales oncology franchise largely keytruda launch hcv treatment zepatier growth vaccine products including gardasilgardasil varivax pneumovax also contributing sales growth higher sales hospital acute care products including bridion noxafil growth within diabetes franchise januvia janumet well higher sales animal health products particularly bravecto increases partially offset sales declines attributable ongoing effects generic biosimilar competition certain products including remicade nasonex along products within diversified brands declines isentress pegintron dulera inhalation aerosol also partially offset revenue growth sales performance reflects decline approximately million due reduced operations company venezuela result evolving economic conditions volatility country sales united states billion increase compared billion within pharmaceutical segment sales united states grew driven primarily launches zepatier bridion along higher sales keytruda gardasilgardasil partially offset lower sales nasonex cubicin dulera inhalation aerosol isentress international sales billion decline compared billion foreign exchange unfavorably affected international sales performance international sales within pharmaceutical segment declined including unfavorable effect foreign exchange largely reflecting declines certain emerging markets offset increase japan sales emerging markets billion decline including unfavorable effect foreign exchange driven primarily reduced operations venezuela partially offset growth markets sales japan grew billion includes favorable effect foreign exchange excluding favorable effect foreign exchange sales decline japan largely driven loss market exclusivity singulair combined ongoing generic erosion products within diversified brands partially offset higher sales belsomra sales europe billion essentially flat compared including unfavorable effect foreign exchange excluding unfavorable effect foreign exchange sales performance europe primarily reflects volume growth keytruda cubicin simponi adempas liptruzet januvia franchise partially offset ongoing biosimilar competition generic erosion certain products particularly remicade pricing pressures region total international sales represented total sales respectively global efforts toward health care cost containment continue exert pressure product pricing market access worldwide united states health care reform contributing increase number patients medicaid program sales pharmaceutical products subject substantial rebates many international markets governmentmandated pricing actions reduced prices generic patented drugs addition austerity measures negatively affected companys revenue performance company anticipates pricing actions austerity measures continue negatively affect revenue performance table contents worldwide sales billion decline compared including unfavorable effect foreign exchange acquisition cubist pharmaceuticals inc cubist divestiture mercks consumer care mcc business well product divestitures termination companys relationship astrazeneca lp azlp also discussed net unfavorable impact sales approximately addition sales performance reflects declines pegintron victrelis remicade pneumovax nasonex vytorin declines partially offset volume growth keytruda januvia janumet gardasilgardasil noxafil simponi implanonnexplanon invanz dulera inhalation aerosol bridion well volume growth animal health products higher thirdparty manufacturing sales january company acquired cubist contributed sales billion mercks revenues company divested certain ophthalmic products several international markets closed july addition october company divested mcc business including prescription rights claritin afrin sales decline attributable divestitures approximately billion billion related consumer care segment million related pharmaceutical segment also company sold us marketing rights saphris antipsychotic indicated treatment schizophrenia bipolar disorder adults resulted revenue million additionally companys relationship azlp terminated june therefore effective july company longer records supply sales azlp supply sales million termination date reflected alliances segment table contents sales companys products follows millions primary care womens health cardiovascular zetia vytorin diabetes januvia janumet general medicine womens health nuvaring implanonnexplanon dulera follistim aq hospital specialty hepatitis zepatier hiv isentress hospital acute care cubicin noxafil invanz cancidas bridion primaxin immunology remicade simponi oncology keytruda emend temodar diversified brands respiratory singulair nasonex cozaarhyzaar arcoxia fosamax zocor vaccines gardasilgardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales cubicin represent sales subsequent cubist acquisition date sales cubicin reflect sales japan pursuant previously existing licensing agreement amounts reflect sales vaccines sold major european markets companys joint venture spmsd results reflected equity income affiliates included income expense net amounts however reflect supply sales spmsd december merck sanofi pasteur terminated spmsd joint venture see note consolidated financial statements pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments animal health healthcare services alliances well consumer care divestiture october alliances segment includes revenue companys relationship azlp termination june primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales also includes approximately million million respectively connection sale marketing rights certain productstable contents pharmaceutical segment primary care womens health cardiovascular combined global sales zetia marketed countries outside united states ezetrol vytorin marketed outside united states inegy medicines lowering ldl cholesterol billion decline compared including unfavorable effect foreign exchange addition company recorded sales million atozet medicine lowering ldl cholesterol company markets certain countries outside united states global sales ezetimibe family including atozet billion growth compared reflecting volume growth europe higher pricing united states largely offset lower sales venezuela due reduced operations country lower volumes united states reflecting part generic competition zetia agreement generic manufacturer launched generic version zetia united states december company experiencing rapid decline us zetia sales company anticipates decline accelerate future periods us patent exclusivity periods zetia vytorin otherwise expire april company anticipates declines us zetia vytorin sales thereafter us sales zetia vytorin billion million respectively company market exclusivity major european markets ezetrol april inegy april combined worldwide sales ezetimibe family billion decline compared including unfavorable effect foreign exchange sales decline driven primarily lower volumes ezetrol canada lost market exclusivity september well lower volumes united states partially offset higher pricing united states pursuant collaboration merck bayer ag bayer see note consolidated financial statements merck lead commercial rights adempas novel cardiovascular drug treatment pulmonary arterial hypertension countries outside americas bayer lead rights americas including united states merck began promoting distributing adempas europe transition merck territories continue merck recorded sales adempas million includes sales mercks marketing territories well mercks share profits sale adempas bayers marketing territories september merck sold marketing rights zontivity united states canada aralez pharmaceuticals inc million upfront payment royalties graduated rates plus potential future consideration dependent upon achievement certain aggregate annual salesbased milestones previously march following several business decisions reduced sales expectations zontivity united states europe company lowered cash flow projections zontivity company utilized market participant assumptions considered several different scenarios determine fair value intangible asset related zontivity compared related carrying value resulted impairment charge million recorded materials production costs diabetes worldwide combined sales januvia janumet medicines help lower blood sugar levels adults type diabetes billion increase compared sales growth driven primarily higher volumes united states europe canada partially offset pricing pressures united states europe lower sales venezuela due companys reduced operations country combined global sales januvia janumet billion essentially flat compared including unfavorable effect foreign exchange sales performance reflects higher volumes pricing united states well volume growth emerging markets europe volume declines comarketed sitagliptin japan due timing sales licensee partially offset growth general medicine womens health worldwide sales nuvaring vaginal contraceptive product million increase compared million increase compared foreign exchange unfavorably affected global sales performance respectively sales growth years largely reflects higher pricing united states volume declines europe partially offset revenue growth august us district court ruled companys delivery system patent nuvaring invalid company appealing verdict us court appeals federal circuit however given us district courts decision may generic entrants us market advance april patent table contents expiration occur company anticipates significant decline us nuvaring sales thereafter us sales nuvaring million result unfavorable us district court decision company evaluated intangible asset related nuvaring impairment concluded impaired intangible asset value nuvaring million december worldwide sales implanonnexplanon singlerod subdermal contraceptive implants grew million increase compared including unfavorable effect foreign exchange sales growth reflects higher demand united states partially offset declines certain emerging markets particularly venezuela implanonnexplanon sales rose million increase compared including unfavorable effect foreign exchange increase driven primarily higher demand united states emerging markets global sales dulera inhalation aerosol combination medicine treatment asthma million decline compared including unfavorable effect foreign exchange decline driven lower sales united sales reflecting competitive pricing pressures partially offset higher demand worldwide sales dulera inhalation aerosol grew million driven primarily higher demand united states global sales follistim aq marketed countries outside united states puregon fertility treatment million decline compared including unfavorable effect foreign exchange sales decline primarily reflects lower volumes europe due part supply issues lower demand certain emerging markets worldwide sales follistim aq million decline compared reflecting unfavorable effect foreign exchange offset higher pricing united states company determined business reasons would terminate north america partnership agreement alkabell included grastek ragwitek allergy immunotherapy tablets sublingual use decision due efficacy safety concerns tablets merck provided alkabell six months notice terminating agreement therefore compounds returned alkabell connection decision company wroteoff million intangible assets related products see note consolidated financial statements hospital specialty hepatitis global sales zepatier million zepatier approved fda january treatment adult patients chronic hcv gt gt infection ribavirin certain patient populations zepatier approved ec july became available european markets late november launches expected continue across eu company also launching zepatier japan emerging markets worldwide sales pegintron treatment chronic hcv declined million decreased million declines driven lower volumes nearly regions availability newer therapeutic options resulted continued loss market share global sales victrelis oral medicine treatment chronic hcv million decline compared sales million driven lower volumes europe emerging markets availability newer therapeutic options resulted continued loss market share sale victrelis de minimis hiv worldwide sales isentress hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection billion decline compared including unfavorable effect foreign exchange sales decline driven primarily lower volumes united states well lower demand pricing europe due competitive pressures partially offset favorable adjustment discount reserves united states higher demand certain emerging markets global sales isentress billion decline compared including unfavorable effect foreign exchange decline driven primarily lower volumes united states lower demand table contents pricing europe due competitive pressures partially offset higher volumes latin america higher pricing united states hospital acute care global sales cubicin iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms billion decline compared us composition patent cubicin expired june company experiencing significant decline us cubicin sales expects decline continue sales decline united states partially offset sales cubicin certain international markets company acquired marketing rights fourth quarter including europe latin america australia new zealand china south africa certain asia pacific countries company anticipates lose market exclusivity cubicin europe worldwide sales noxafil prevention invasive fungal infections grew million driven primarily higher pricing united states volume growth europe reflecting ongoing positive impact approval new formulations higher demand emerging markets global sales noxafil rose million driven pricing higher demand united states well volume growth europe reflecting positive impact approval new formulations foreign exchange unfavorably affected global sales performance global sales invanz treatment certain infections million decline compared including unfavorable effect foreign exchange sales performance reflects volume growth certain emerging markets higher pricing united states largely offset decline venezuela worldwide sales invanz million increase compared reflecting higher sales united states volume growth emerging markets partially offset unfavorable effect foreign exchange company lose us patent protection invanz november company anticipates significant decline us invanz sales thereafter us sales invanz million global sales cancidas antifungal product sold primarily outside united states million decline compared reflecting unfavorable effect foreign exchange pricing declines europe offset higher volumes certain emerging markets particularly china worldwide sales cancidas million decrease compared reflecting unfavorable effect foreign exchange volume declines certain emerging markets eu compound patent cancidas expires april company anticipates decline cancidas sales european markets thereafter sales cancidas europe million global sales bridion reversal two types neuromuscular blocking agents used surgery million growth compared including favorable effect foreign exchange sales growth reflects volume growth markets including united states approved fda december partially offset decline venezuela due reduced operations company country sales bridion increased million driven volume growth international markets foreign exchange unfavorably affected global sales performance october merck announced fda approved zinplava injection mgml zinplava indicated reduce recurrence clostridium difficile infection cdi patients years age older receiving antibacterial drug treatment cdi high risk cdi recurrence zinplava became available united states february zinplava approved ec january company anticipates zinplava available eu march immunology sales remicade treatment inflammatory diseases marketed company europe russia turkey billion decline compared billion decline compared foreign exchange unfavorably affected sales performance february company lost market exclusivity remicade major european markets longer market exclusivity marketing territories company experiencing pricing volume declines markets result biosimilar competition expects declines continue table contents sales simponi oncemonthly subcutaneous treatment certain inflammatory diseases marketed company europe russia turkey million increase compared including unfavorable effect foreign exchange sales growth driven primarily higher volumes europe reflecting part ongoing positive impact ulcerative colitis indication sales simponi million essentially flat compared driven higher demand europe reflecting part ongoing positive impact ulcerative colitis indication offset unfavorable effect foreign exchange oncology sales keytruda antipd therapy billion million million yearoveryear increases primarily reflect higher sales united states europe emerging markets company continues launch keytruda october merck announced fda approved keytruda firstline treatment patients nsclc whose tumors high pdl expression tps determined fdaapproved test egfr alk genomic tumor aberrations new indication keytruda antipd therapy approved firstline treatment setting patients addition fda approved labeling update include data keynote secondline greater treatment setting patients metastatic nsclc whose tumors express pdl tps determined fdaapproved test disease progression platinumcontaining chemotherapy patients egfr alk genomic tumor aberrations disease progression fdaapproved therapy aberrations prior receiving keytruda december keytruda approved japan treatment certain patients pdlpositive unresectable advancedrecurrent nsclc first secondline treatment settings additionally january ec approved keytruda firstline treatment metastatic nsclc adults whose tumors high pdl expression tps egfr alk positive tumor mutations august merck announced fda approved keytruda treatment patients recurrent metastatic head neck squamous cell carcinoma hnscc disease progression platinumcontaining chemotherapy keytruda approved united states eu treatment previously untreated metastatic nsclc patients whose tumors express high levels pdl previously treated metastatic nsclc patients whose tumors express pdl well treatment advanced melanoma keytruda also approved united states previously treated recurrent metastatic hnscc company launched keytruda markets globally merck five sblas priority review fda keytruda including use combination chemotherapy firstline treatment patients metastatic advanced nonsquamous nsclc regardless pdl expression egfr alk genomic tumor aberrations treatment patients classical hodgkin lymphoma treatment previously treated patients advanced microsatellite instabilityhigh cancer firstline treatment patients locally advanced metastatic urothelial cancer including bladder cancers secondline treatment patients locally advanced metastatic urothelial cancer disease progression platinumcontaining chemotherapy company plans additional regulatory filings united states countries keytruda clinical development program includes studies across broad range cancer types see research development january merck entered settlement license agreement resolve worldwide patent infringement litigation related keytruda see note consolidated financial statements global sales emend prevention chemotherapyinduced postoperative nausea vomiting million increase compared including unfavorable effect foreign exchange largely reflecting higher pricing united states partially offset volume declines japan february merck announced fda approved supplemental new drug application singledose emend injection prevention delayed nausea vomiting adults receiving initial repeat courses moderately emetogenic chemotherapy worldwide sales emend million decline reflecting unfavorable effect foreign exchange partially offset higher pricing united states volume growth europe table contents diversified brands mercks diversified brands include human health pharmaceutical products approaching expiration marketing exclusivity longer protected patents developed markets continue core part companys offering markets around world respiratory worldwide sales singulair onceaday oral medicine chronic treatment asthma relief symptoms allergic rhinitis million decrease compared including favorable effect foreign exchange sales performance primarily reflects lower volumes japan patents provided market exclusivity singulair japan expired february october result company experiencing singulair volume declines japan expects decline continue singulair sales japan million years prior company lost market exclusivity singulair united states major international markets exception japan company longer market exclusivity singulair major market global sales singulair million decline compared including unfavorable effect foreign exchange sales decline driven primarily lower volumes japan lower demand europe result generic competition global sales nasonex inhaled nasal corticosteroid treatment nasal allergy symptoms million decline compared driven primarily lower volumes united states resulting generic competition march apotex launched generic version nasonex united states pursuant june us district court district new jersey ruling upheld appeal us court appeals federal circuit holding apotexs generic version nasonex infringe companys formulation patent accordingly company experiencing substantial decline us nasonex sales expects decline continue decline global nasonex sales also driven lower volumes pricing europe ongoing generic erosion lower sales venezuela due reduced operations company country worldwide sales nasonex million decline compared including unfavorable effect foreign exchange decline driven primarily lower volumes united states reflecting competition alternative generic treatment options well supply constraints addition lower volumes pricing europe ongoing generic erosion also contributed nasonex sales decline global sales cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatments hypertension declined million decreased million foreign exchange unfavorably affected global sales performance respectively patents provided market exclusivity cozaar hyzaar united states major international markets expired accordingly company experiencing declines cozaar hyzaar sales expects declines continue vaccines following discussion vaccines include sales vaccines sold major european markets spmsd companys joint venture sanofi pasteur sanofi results reflected equity income affiliates included income expense net see selected joint venture affiliate information supply sales spmsd however included december merck sanofi terminated spmsd ended joint vaccines operations europe see note consolidated financial statements beginning merck record vaccine sales european markets previously part spmsd joint venture mercks sales gardasilgardasil vaccines help prevent certain cancers diseases caused certain types hpv billion growth compared sales growth driven primarily higher volumes pricing united states well higher demand certain emerging markets partially offset decline government tenders brazil october fda approved dose vaccination regimen gardasil use girls boys years age us centers disease control preventions advisory committee immunization practices voted recommend dose vaccination regimen certain year olds company anticipates dose vaccination regimen unfavorable effect sales gardasil period transition mercks sales gardasilgardasil billion increase compared including unfavorable effect foreign exchange sales growth table contents driven primarily higher sales united states resulting higher pricing increased volumes reflecting timing public sector purchases well increased government tenders asia pacific region partially offset declines latin america due price volume gardasil mercks valent hpv vaccine approved fda december use females years age males years age gardasil includes greatest number hpv types available hpv vaccine december fda approved expanded age indication gardasil include use males years age prevention anal cancers precancerous dysplastic lesions genital warts caused certain hpv types company party certain thirdparty license agreements respect gardasilgardasil including crosslicense settlement agreement glaxosmithkline result agreements company pays royalties worldwide gardasilgardasil sales vary country included materials production costs mercks sales proquad pediatric combination vaccine help protect measles mumps rubella varicella million million million sales growth compared driven primarily higher demand pricing united states sales growth compared primarily reflects higher sales united states reflecting increased volumes driven part measles outbreaks united states well higher pricing mercks sales mmr ii vaccine help protect measles mumps rubella million million million sales performance compared driven higher demand resulting measles outbreaks united states mercks sales varivax vaccine help prevent chickenpox varicella million million million sales growth compared driven primarily higher sales united states reflecting effects public sector purchasing higher pricing partially offset lower demand volume growth certain emerging markets reflecting timing government tenders also contributed sales increase compared sales growth compared reflects higher volumes certain emerging markets higher pricing united states partially offset lower volumes united states mercks sales zostavax vaccine help prevent shingles herpes zoster adults years age older million decline compared including unfavorable effect foreign exchange decline driven primarily lower volumes united states partially offset higher pricing united states higher demand certain emerging markets mercks sales zostavax million decline compared including unfavorable effect foreign exchange sales performance compared reflects lower volumes united states partially offset higher demand canada higher pricing united states company continuing educate us customers broad managed care coverage zostavax process obtaining reimbursement merck continuing launch zostavax outside united states mercks sales rotateq vaccine help protect rotavirus gastroenteritis infants children million increase compared million decline compared including unfavorable effect foreign exchange sales performance periods driven primarily effects public sector purchasing united states volume growth certain emerging markets also contributed sales growth mercks sales pneumovax vaccine help prevent pneumococcal disease million increase compared driven primarily higher volumes pricing united states higher demand certain emerging markets mercks sales pneumovax million decrease compared driven primarily lower demand united states sales declines emerging markets foreign exchange favorably affected sales performance unfavorably affected sales performance segments companys segments animal health healthcare services alliances segments material separate reporting alliances segment includes revenue azlp termination companys relationship azlp june see selected joint venture affiliate information table contents prior disposition october company also consumer care segment sales billion animal health animal health includes pharmaceutical vaccine products prevention treatment control disease major farm companion animal species animal health sales affected competition frequent introduction generic products worldwide sales animal health products billion billion billion global sales animal health products increased compared including unfavorable effect foreign exchange sales growth primarily reflects volume growth across species areas particularly products companion animals driven primarily higher sales bravecto well poultry swine products worldwide sales animal health products declined compared including unfavorable effect foreign exchange sales performance reflects volume growth companion animal products driven primarily higher sales bravecto began launching europe united states well volume growth swine aqua products may company received marketing approval european medicines agency ema bravecto spoton solution cats dogs july company received approval united states market product tradename bravecto topical july merck announced executed agreement acquire controlling interest valle leading privately held producer animal health products brazil see note consolidated financial statements costs expenses millions change change materials production marketing administrative research development restructuring costs income expense net greater materials production materials production costs billion billion billion costs include expenses amortization intangible assets recorded connection business acquisitions totaled billion billion billion costs also include intangible asset impairment charges million million billion respectively related marketed products intangibles see note consolidated financial statements company may recognize additional noncash impairment charges future related intangible assets measured fair value capitalized connection business acquisitions charges could material addition expenses include million amortization purchase accounting adjustments cubists inventories also included materials production costs expenses associated restructuring activities amounted million million million respectively including accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed gross margin compared improvement gross margin compared driven primarily lower net impact amortization intangible assets purchase accounting adjustments inventories well intangible asset impairment charges restructuring costs noted reduced gross margin percentage points compared percentage points lower inventory writeoffs favorable effects foreign exchange also contributed gross margin improvement compared gross margin improvement compared driven primarily favorable effects foreign exchange lower inventory writeoffs well table contents net impact acquisitions divestitures amortization intangible assets purchase accounting adjustments inventories well restructuring intangible asset impairment charges noted reduced gross margin percentage points marketing administrative marketing administrative expenses billion decline compared driven largely lower acquisition divestiturerelated costs favorable effects foreign exchange lower administrative expenses legal defense costs well lower selling costs higher promotional spending largely related product launches higher restructuring costs partially offset decline expenses billion decline compared largely reflecting favorable effects foreign exchange divestiture mcc additional expenses related health care reform fee discussed lower restructuring costs well lower selling costs partially offset higher promotional spending largely related product launches higher costs related january acquisition cubist higher acquisition divestiturerelated costs expenses include acquisition divestiturerelated costs million million million respectively consisting integration transaction certain costs related business acquisitions including severance costs part companys formal restructuring programs well transaction certain costs related divestitures businesses acquisition divestiturerelated costs include costs related acquisition cubist see note consolidated financial statements expenses also include restructuring costs million million million respectively related primarily accelerated depreciation facilities closed divested separation costs associated sales force reductions incurred reflected restructuring costs discussed july internal revenue service irs issued final regulations annual nontax deductible health care reform fee imposed patient protection affordable care act based allocation companys market share prior year branded pharmaceutical sales certain government programs final irs regulations accelerated recognition criteria fee obligation one year year underlying sales used allocate fee occurred rather year fee paid result change merck recorded additional year expense million research development research development rd expenses billion compared billion increase driven primarily higher acquired inprocess research development iprd impairment charges increased clinical development spending higher restructuring licensing costs partially offset reduction expenses associated decrease estimated fair value measurement liabilities contingent consideration well favorable effects foreign exchange rd expenses billion decline compared driven primarily favorable effects foreign exchange expenses recognized increase estimated fair value liabilities contingent consideration lower restructuring costs charge related collaboration bayer ag bayer divestiture mcc partially offset acquisition cubist higher licensing costs higher clinical development spending rd expenses comprised costs directly incurred merck research laboratories mrl companys research development division focuses human healthrelated activities approximately billion billion billion also included rd expenses costs incurred divisions support rd activities including depreciation production general administrative well licensing activity certain costs operating segments including pharmaceutical animal health segments aggregate billion billion billion respectively rd expenses also include iprd impairment charges billion million million respectively see research development company may recognize additional noncash impairment charges future related cancellation delay pipeline programs measured fair value capitalized connection business acquisitions charges could material addition rd expenses include expense income related changes estimated fair value measurement liabilities contingent consideration recorded connection acquisitions company recorded reduction expenses million million respectively decrease estimated fair value liabilities contingent consideration related discontinuation delay certain programs see note consolidated financial statements company recorded charge million table contents increase estimated fair value liabilities contingent consideration rd expenses also reflect million million million respectively accelerated depreciation asset abandonment costs associated restructuring activities restructuring costs company incurs substantial costs restructuring program activities related mercks productivity cost reduction initiatives well connection integration certain acquired businesses company commenced actions global restructuring programs designed streamline cost structure actions programs include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company also continues reduce global real estate footprint improve efficiency manufacturing supply network nonfacility related restructuring actions programs substantially complete remaining activities primarily relate ongoing facility rationalizations restructuring costs primarily representing separation related costs associated restructuring activities million million billion respectively separation costs million million million respectively incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated merck eliminated approximately positions positions positions related restructuring activities position eliminations comprised actual headcount reductions elimination contractors vacant positions also included restructuring costs asset abandonment shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included materials production marketing administrative research development discussed company recorded aggregate pretax costs billion billion billion related restructuring program activities see note consolidated financial statements company expects substantially complete remaining actions programs end incur approximately million additional pretax costs income expense net income expense net million expense billion expense billion income details components income expense net see note consolidated financial statements segment profits millions pharmaceutical segment profits nonreportable segment profits income income taxes segment profits comprised segment sales less standard costs certain operating expenses directly incurred segment components equity income loss affiliates certain depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate materials production costs standard costs majority research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits acquisition divestiturerelated costs including amortization purchase accounting adjustments intangible asset impairment charges restructuring costs taxes paid joint venture level portion equity income additionally segment profits reflect expenses corporate manufacturing cost centers table contents miscellaneous income expense unallocated items including charge related settlement worldwide keytruda patent litigation gains divestitures net charge related settlement vioxx shareholder class action litigation gain astrazenecas option exercise foreign exchange losses related devaluation companys net monetary assets venezuela loss extinguishment debt additional year expense related health care reform fee reflected table also included miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales pharmaceutical segment profits grew compared primarily reflecting higher sales pharmaceutical segment profits declined compared primarily reflecting unfavorable effects foreign exchange taxes income effective income tax rates reflect impacts acquisition divestiturerelated costs include billion iprd impairment charges well restructuring costs beneficial impact foreign earnings effective income tax rate also reflects favorable impact net benefit million related settlement certain federal income tax issues impact net charge related settlement vioxx shareholder class action litigation fully deductible combined us federal state tax rates favorable impact tax legislation enacted fourth quarter well unfavorable effect nontax deductible foreign exchange losses related venezuela see note consolidated financial statements effective income tax rate reflects impact gain divestiture mcc taxed combined us federal state tax rates addition effective income tax rate includes net tax benefit million recorded connection astrazenecas option exercise see note consolidated financial statements benefit approximately million associated capital loss generated connection sale sirna see note consolidated financial statements effective income tax rate also includes unfavorable impact additional year expense nontax deductible health care reform fee company recorded accordance final regulations issued irs company examination numerous tax authorities various jurisdictions globally ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures however one item currently discussion irs relating examination company concluded position sustained upon audit however item result unfavorable outcome settlement could material adverse impact companys financial position liquidity results operations net income earnings per common share net income attributable merck co inc billion billion billion eps nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance merck providing management believes information enhances investors understanding companys results permits investors understand management assesses performance nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items considered nonrecurring consist acquisition divestiturerelated costs restructuring costs certain items excluded items significant components understanding assessing financial performance nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap eps management uses measures internally planning forecasting purposes measure performance company along metrics senior managements annual compensation derived part using nongaap income nongaap eps since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation table contents similar measures companies information nongaap income nongaap eps considered addition substitute superior net income eps prepared accordance generally accepted accounting principles united states gaap reconciliation gaap financial measures nongaap financial measures follows millions except per share amounts pretax income reported gaap increase decrease excluded items acquisition divestiturerelated costs restructuring costs items charge related settlement worldwide keytruda patent litigation foreign currency devaluation related venezuela net charge related settlement vioxx shareholder class action litigation gain sale certain migraine clinical development programs gain divestiture certain ophthalmic products gain divestiture merck consumer care gain astrazeneca option exercise loss extinguishment debt additional year expense health care reform fee taxes income reported gaap estimated tax benefit provision excluded items net tax benefits settlements federal income tax issues tax benefits related sale sirna therapeutics inc subsidiary nongaap net income less net income attributable noncontrolling interests reported gaap acquisition divestiturerelated costs attributable noncontrolling interests nongaap net income attributable merck co inc eps assuming dilution reported gaap eps difference nongaap eps assuming dilution estimated tax impact excluded items determined applying statutory rate originating territory nongaap adjustments amount includes net benefit million recorded connection astrazenecas option exercise represents difference calculated gaap eps calculated nongaap eps may different amount calculated dividing impact excluded items weightedaverage shares applicable year acquisition divestiturerelated costs nongaap income nongaap eps exclude impact certain amounts recorded connection business acquisitions divestitures amounts include amortization intangible assets amortization purchase accounting adjustments inventories well intangible asset impairment charges expense income related changes estimated fair value measurement contingent consideration also excluded integration transaction certain costs associated business acquisitions including severance costs part table contents companys formal restructuring programs well transaction certain costs associated divestitures businesses restructuring costs nongaap income nongaap eps exclude costs related restructuring actions see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions restructuring costs also include asset abandonment shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation costs certain items nongaap income nongaap eps exclude certain items items adjusted evaluating individual basis considering quantitative qualitative aspects typically consist items unusual nature significant results particular period indicative future operating results excluded nongaap income nongaap eps charge settle worldwide patent litigation related keytruda see note consolidated financial statements excluded nongaap income nongaap eps foreign exchange losses related devaluation companys net monetary assets venezuela see note consolidated financial statements net charge related settlement vioxx shareholder class action litigation see note consolidated financial statements gain sale certain migraine clinical development programs see note consolidated financial statements gain divestiture companys remaining ophthalmics business international markets see note consolidated financial statements well net tax benefit related settlement certain federal income tax issues see note consolidated financial statements excluded nongaap income nongaap eps certain gains including gain divestiture mcc see note consolidated financial statements gain recognized conjunction astrazenecas option exercise including related net tax benefit transaction see note consolidated financial statements gain divestiture certain ophthalmic products several international markets see note consolidated financial statements well loss extinguishment debt see note consolidated financial statements additional year expense related health care reform fee discussed tax benefits sale companys sirna therapeutics inc sirna subsidiary see note consolidated financial statements research development chart reflecting companys current research pipeline february set forth item business research development research development update company currently several candidates regulatory review united states keytruda fdaapproved antipd therapy clinical development expanded indications different cancer types keytruda currently approved treatment nsclc melanoma advanced melanoma head neck cancer see pharmaceutical segment february fda accepted review two sblas keytruda patients locally advanced metastatic urothelial cancer including bladder cancers application firstline use granted priority review treatment patients ineligible cisplatincontaining therapy application secondline use granted priority review patients disease progression platinumcontaining chemotherapy prescription drug user fee act pdufa action date applications june fda previously granted breakthrough therapy designation keytruda secondline treatment patients locally advanced metastatic urothelial cancer disease progression platinumcontaining chemotherapy january fda accepted review sbla keytruda plus chemotherapy pemetrexed plus carboplatin firstline treatment patients metastatic advanced nonsquamous nsclc regardless table contents pdl expression egfr alk genomic tumor aberrations first application regulatory approval keytruda combination another treatment fda granted priority review pdufa action date may sbla reviewed fdas accelerated approval program december fda accepted review sbla keytruda treatment patients refractory classical hodgkin lymphoma patients relapsed three prior lines therapy fda granted priority review pdufa action date march sbla reviewed fdas accelerated approval program november fda accepted review sbla keytruda treatment previously treated patients advanced microsatellite instabilityhigh msih cancer fda granted priority review pdufa action date march sbla reviewed fdas accelerated approval program fda recently granted breakthrough therapy designation keytruda unresectable metastatic msih noncolorectal cancer previously granted treatment patients unresectable metastatic msih colorectal cancer additionally keytruda also received breakthrough therapy designation fda treatment patients primary mediastinal bcell lymphoma refractory relapsed two prior lines therapy fdas breakthrough therapy designation intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints keytruda clinical development program consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including bladder colorectal esophageal gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma multiple myeloma nasopharyngeal nsclc ovarian prostate renal triplenegative breast many currently phase clinical development trials planned cancers mk investigational followon biologic insulin glargine candidate treatment patients type type diabetes review fda mk approved eu january mk developed collaboration partially funded samsung bioepis v investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda developed approved commercialized partnership merck sanofi vaccine designed help protect six important diseases diphtheria tetanus pertussis whooping cough polio poliovirus types invasive disease caused haemophilus influenzae type b hib hepatitis b november fda issued complete response letter crl respect biologics license application v companies reviewing crl plan communication fda february ec granted marketing authorization v prophylaxis diphtheria tetanus pertussis hepatitis b poliomyelitis invasive disease caused hib infants toddlers age weeks v marketed vaxelis eu addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed mk verubecestat investigational small molecule inhibitor betasite amyloid precursor protein cleaving enzyme bace treatment alzheimers disease february merck announced external data monitoring committee edmc recommended termination phase epoch study verubecestat mildtomoderate alzheimers disease based low probability success study edmc recommended separate phase study apecs evaluating verubecestat amnestic mild cognitive impairment due alzheimers disease also known prodromal alzheimers disease continue planned estimated primary completion date apecs study fully enrolled february mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raising hdlc reducing ldl c anacetrapib evaluated patient eventdriven cardiovascular clinical outcomes trial sponsored oxford university reveal randomized evaluation effects anacetrapib lipidmodification involving patients preexisting vascular disease november table contents merck announced data monitoring committee dmc reveal outcomes study completed planned review unblinded study data recommended study continue changes dmc reviewed safety efficacy data study included assessment futility merck remains blinded actual results analysis reveal safety efficacy data study last patients last visit occurred january company anticipates receiving topline results study midyear mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approved carbapenem antibiotic fda designated combination qualified infectious disease product designated fast track status treatment hospitalacquired bacterial pneumonia ventilatorassociated bacterial pneumonia complicated intraabdominal infections complicated urinary tract infections mk letermovir investigational oral oncedaily intravenous infusion antiviral candidate prevention clinicallysignificant cytomegalovirus cmv infection letermovir received orphan drug status eu united states also granted fast track designation october merck announced pivotal phase clinical study letermovir met primary endpoint global multicenter randomized placebocontrolled study evaluated efficacy safety letermovir adult years older cmvseropositive recipients allogeneic hematopoietic stem cell transplant merck plans submit regulatory applications approval letermovir united states eu mk ertugliflozin investigational oral sglt inhibitor evaluated treatment type diabetes collaboration pfizer inc pfizer september merck pfizer announced phase study vertis sita ertugliflozin met primary endpoint mg mg daily doses ertugliflozin showed significantly greater reductions ac average measure blood glucose past two three months added patients background sitagliptin metformin ertugliflozin also studied combination januvia sitagliptin metformin december merck submitted new drug applications fda ertugliflozin two fixeddose combinations mka ertugliflozin plus januvia mkb ertugliflozin plus metformin company anticipates response fda first quarter ertugliflozin two fixeddose combinations currently review eu terms collaboration agreement pfizer merck make million milestone payment pfizer mkj investigational fixeddose combination sitagliptin ipragliflozin development commercialization japan collaboration astellas pharma inc astellas ipragliflozin sglt inhibitor codeveloped astellas kotobuki pharmaceutical co ltd kotobuki approved use japan copromoted merck kotobuki v investigational rvsvzebov ebola vaccine candidate studied large scale phase clinical trials november merck newlink genetics announced exclusive licensing collaboration agreement investigational ebola vaccine december merck announced application emergency use assessment listing eual v accepted review world health organization according eual process designed expedite availability vaccines needed public health emergencies another outbreak ebola decision grant v eual status based data regarding quality safety efficacyeffectiveness well riskbenefit analysis emergency use eual designation allows emergency use vaccine remains investigational yet licensed commercial distribution july merck announced fda granted v breakthrough therapy designation ema granted vaccine candidate prime priority medicines status december end study results ring vaccination trial reported lancet supporting july interim assessment v offers substantial protection ebola virus disease reported cases among vaccinated individuals days vaccination randomized nonrandomized clusters results ongoing studies anticipated second half mk vericiguat investigational treatment heart failure studied phase clinical trial patients suffering chronic heart failure development vericiguat part worldwide strategic collaboration merck bayer see note consolidated financial statements v inactivated varicella zoster virus vaccine development prevention herpes zoster company completed phase trial autologous hematopoietic cell transplant patients conducting another phase trial patients solid tumor malignancies undergoing chemotherapy hematological malignancies table contents study autologous hematopoietic cell transplant patients met primary endpoints merck presented results study american society blood marrow transplantation meetings february mk doravirine investigational nonnucleoside reverse transcriptase inhibitor developed merck treatment hiv infection february company received positive results first phase study showing doravirine noninferior alternative regimen achieving maintaining hiv suppression infected adults weeks treatment company also divested discontinued certain drug candidates merck announced discontinuing development odanacatib investigational cathepsin k inhibitor osteoporosis seek regulatory approval use merck previously reported numeric imbalance adjudicated stroke events pivotal phase fracture outcomes study postmenopausal women company decided discontinue development independent adjudication analysis major adverse cardiovascular events confirmed increased risk stroke company determined business reasons would terminate north america partnership agreement alkabell included mk investigational allergy immunotherapy tablet house dust mite allergy merck given alkabell six months notice terminating agreement therefore compound returned alkabell decision due efficacy safety concerns connection decision company recorded iprd impairment charge see note consolidated financial statements company also decided business reasons discontinue clinical development mkb referred next generation ring investigational combination etonogestrel estradiol vaginal ring contraception treatment dysmenorrhea women seeking contraception decision due efficacy safety concerns result decision company recorded iprd impairment charge see note consolidated financial statements merck announced business reasons proceed submitting marketing applications omarigliptin investigational onceweekly dpp inhibitor united states europe decision result concerns efficacy safety omarigliptin company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed making externally sourced programs greater component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies company also reviews pipeline examine candidates may provide value outlicensing company continues evaluate certain latestage clinical development platform technology assets determine outlicensing sale potential companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases neurodegenerative diseases respiratory diseases acquired inprocess research development connection business acquisitions company recorded fair value inprocess research projects time acquisition yet reached technological feasibility december balance iprd billion company recorded iprd projects obtained connection acquisitions afferent iomet discussed table contents million million million respectively iprd projects received marketing approval major market company began amortizing assets based estimated useful lives iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development company realize future cash flows estimated recorded iprd acquisition date company may also recover research development expenditures made since acquisition develop program circumstances occur companys future operating results could adversely affected company may recognize impairment charges charges could material company recorded billion iprd impairment charges within research development expenses amount billion relates clinical development program uprifosbuvir nucleotide prodrug clinical development evaluated treatment hcv company determined recent changes product profile well changes mercks expectations pricing market opportunity taken together constituted triggering event required company evaluate uprifosbuvir intangible asset impairment utilizing market participant assumptions considering different scenarios company concluded best estimate current fair value intangible asset related uprifosbuvir million resulting recognition pretax impairment charge noted iprd impairment charges also include charges million million related discontinuation programs obtained connection acquisitions ccam biotherapeutics ltd oncoethix respectively resulting unfavorable efficacy data additional million relates programs obtained connection smartcells acquisition following decision terminate lead compound due lack efficacy pursue backup compound reduced projected future cash flows iprd impairment charges also include million related inlicensed program house dust mite allergies business reasons returned licensor remaining iprd impairment charges primarily relate deprioritized pipeline programs deemed alternative use period including million impairment charge investigational candidate contraception discontinuation delay certain clinical development programs resulted reduction related liabilities contingent consideration see note consolidated financial statements company recorded million iprd impairment charges million related surotomycin clinical development program company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge noted company recorded million iprd impairment charges primarily result changes cash flow assumptions certain compounds obtained connection companys joint venture supera farma laboratorios sa well discontinuation certain animal health programs additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval december estimated costs complete projects acquired connection acquisitions phase development human health approximately million acquisitions research collaborations license agreements merck continues remain focused pursuing opportunities potential drive near longterm growth certain recent significant transactions described merck actively monitoring landscape growth opportunities meet companys strategic criteria july merck acquired afferent privately held pharmaceutical company focused development therapeutic candidates targeting px receptor treatment common poorlymanaged neurogenic table contents conditions afferents lead investigational candidate mk formerly af selective nonnarcotic orallyadministered px antagonist evaluated phase b clinical trial treatment refractory chronic cough well phase clinical trial idiopathic pulmonary fibrosis cough total consideration transferred million included cash paid outstanding afferent shares million well sharebased compensation payments settle equity awards attributable precombination service cash paid transaction costs behalf afferent addition former afferent shareholders eligible receive total additional million contingent upon attainment certain clinical development commercial milestones multiple indications candidates including mk transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date company determined fair value contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream adjusted expected timing payment using appropriate discount rate dependent nature timing milestone payment merck recognized intangible asset iprd million net deferred tax liabilities million net assets million primarily consisting cash acquired excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair value identifiable intangible asset related iprd determined using income approach fair value estimated based upon assets probability adjusted future net cash flows reflects stage development project associated probability successful completion net cash flows discounted present value using discount rate actual cash flows likely different assumed june merck moderna entered strategic collaboration license agreement develop commercialize novel mrnabased personalized cancer vaccines development program entail multiple studies several types cancer include evaluation mrnabased personalized cancer vaccines combination mercks keytruda pursuant terms agreement merck made upfront cash payment moderna million recorded research development expenses following human proof concept studies merck right elect make additional payment moderna merck exercises right two companies equally share cost profits worldwide collaboration development personalized cancer vaccines moderna right elect copromote personalized cancer vaccines united states agreement entails exclusivity around combinations keytruda moderna merck ability combine mrnabased personalized cancer vaccines nonpd agents january merck acquired iomet privately held ukbased drug discovery company focused development innovative medicines treatment cancer particular emphasis fields cancer immunotherapy cancer metabolism acquisition provides merck iomets preclinical pipeline ido indoleaminedioxygenase tdo tryptophandioxygenase dualacting idotdo inhibitors transaction accounted acquisition business total purchase consideration transaction included cash payment million future additional milestone payments million contingent upon certain clinical regulatory milestones achieved company determined fair value contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream adjusted expected timing payment utilizing discount rate merck recognized intangible assets iprd million net deferred tax assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value also using discount rate actual cash flows likely different assumed selected joint venture affiliate information sanofi pasteur msd december merck sanofi terminated equallyowned joint venture formed develop market vaccines europe see note consolidated financial statements table contents sales joint venture products prior termination follows millions gardasilgardasil influenza vaccines viral vaccines rotateq zostavax hepatitis vaccines vaccines astrazeneca lp june astrazeneca exercised option resulted redemption mercks remaining interest astrazeneca lp azlp partnership merck astrazeneca million cash see note consolidated financial statements amount million reflected estimate fair value mercks interest nexium prilosec products sold azlp portion exercise price subject trueup based actual sales closing june deferred recognized income million million million respectively income expense net contingency eliminated sales occurred deferred income amount fully amortized first quarter company began recognizing income corresponding receivable amounts due merck astrazeneca based sales performance nexium prilosec subject trueup june company recognized million income included income expense net remaining exercise price million primarily represents multiple ten times mercks average annual profit allocation partnership three years prior exercise merck recognized million gain within income expense net company also recognized noncash gain approximately million within income expense net resulting retirement billion preferred stock elimination companys billion investment azlp million reduction goodwill transaction resulted net tax benefit million primarily reflecting reversal deferred taxes azlp investment balance prior termination merck recorded revenue azlp million earned partnership returns million recorded equity income affiliates included income expense net capital expenditures capital expenditures billion billion billion expenditures united states billion million million depreciation expense billion billion billion billion billion billion respectively applied locations united states total depreciation expense included accelerated depreciation million million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operations total debt cash provided operating activities billion billion billion cash provided operating activities reflects net payment approximately million fund table contents vioxx shareholder class action litigation settlement covered insurance proceeds see note consolidated financial statements cash provided operating activities reflects approximately billion taxes paid divestiture mcc cash provided operating activities continues companys primary source funds finance operating needs capital expenditures portion treasury stock purchases dividends paid shareholders cash used investing activities billion compared billion lower use cash driven primarily cash used acquisition cubist well lower purchases securities investments partially offset lower proceeds sales securities investments use cash acquisitions afferent staywell cash used investing activities billion compared million primarily reflecting cash received divestiture mcc higher cash received dispositions businesses connection astrazenecas option exercise well cash used acquisition cubist partially offset lower purchases securities investments higher proceeds sales securities investments cash used acquisition idenix cash payment made upon formation collaboration bayer cash used financing activities billion compared billion driven primarily lower proceeds issuance debt partially offset decrease shortterm borrowings prior year lower payments debt lower purchases treasury stock higher proceeds exercise stock options cash used financing activities billion compared billion driven primarily higher proceeds issuance debt lower payments debt lower purchases treasury stock partially offset lower proceeds exercise stock options decrease shortterm borrowings company recorded charges million related devaluation net monetary assets venezuela large majority cash see note consolidated financial statements december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments generally cash investments held foreign subsidiaries would subject significant tax payments cash investments repatriated form dividends company records us deferred tax liabilities certain unremitted earnings amounts earned overseas expected indefinitely reinvested outside united states accrual us taxes provided amount cash investments held us foreign subsidiaries fluctuates due variety factors including timing receipt payments normal course business cash provided operating activities united states continues companys primary source funds finance domestic operating needs capital expenditures portion treasury stock purchases dividends paid shareholders companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations keytruda patent litigation settlement unrecognized tax benefits operating leases includes future inventory purchases company committed connection certain divestitures february million floating rate notes matured repaid december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including billion reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made table contents purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising amounts reflected research development obligations include contingent milestone payments company make million milestone payment connection clinical program developed collaboration see research development also excluded research development obligations potential future funding commitments approximately million investments research venture capital funds loans payable current portion longterm debt reflects million longdated notes subject repayment option holders required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing approximately million us pension plans million international pension plans million postretirement benefit plans november company issued billion principal amount senior unsecured notes consisting million principal amount notes due million principal amount notes due company intends use net proceeds offering billion general corporate purposes including without limitation repayment outstanding commercial paper borrowings indebtedness upcoming maturities june company terminated existing credit facility entered new billion fiveyear credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility december company filed securities registration statement us securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years february merck issued billion aggregate principal amount senior unsecured notes company used portion net proceeds offering billion repay commercial paper issued substantially finance companys acquisition cubist remaining net proceeds used general corporate purposes including repurchases companys common stock repayment outstanding commercial paper borrowings debt maturities also february company redeemed billion legacy cubist debt acquired acquisition see note consolidated financial statements october company issued billion principal amount senior unsecured notes net proceeds offering billion used part repay debt validly tendered connection tender offers launched company certain outstanding notes debentures company paid billion aggregate consideration applicable purchase price together accrued interest redeem billion principal amount debt november merck redeemed additional billion principal amount senior unsecured notes effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november board directors declared quarterly dividend per share companys common stock payable january march mercks board directors authorized additional purchases billion mercks common stock treasury treasury stock purchase authorization time limit made time table contents openmarket transactions block transactions exchange privately negotiated transactions company purchased billion common stock million shares treasury company approximately billion remaining march share repurchase program company purchased billion billion common stock respectively previously authorized share repurchase programs financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted foreign currency denominated sales portion forecasted sales hedged based assessments cost benefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options merck principally sells foreign currency revenue hedging program uniform weakening us dollar would yield largest overall potential loss market value hedge instruments market value mercks hedges would declined estimated million million december respectively uniform weakening us dollar market value determined using foreign exchange option pricing model holding factors except exchange rates constant although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows company manages operating activities net asset positions local level order mitigate effect exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statements cash flows sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened currency exposures company december income taxes would declined approximately million company net short payable position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange december company net long receivable table contents position relative major foreign currencies consideration forward contracts therefore uniform strengthening us dollar would reduced income taxes approximately million measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows since january venezuela designated hyperinflationary result local foreign operations remeasured us dollars impact recorded results operations venezuelan government identified multiple exchange rates included cencoex rate vef per us dollar simadi rate venezuelan government indicated essential goods including food medicine would remain cencoex rate second quarter upon evaluation evolving economic conditions venezuela volatility country combined decline transactions settled cencoex rate company determined unlikely outstanding net monetary assets would settled cencoex rate accordingly second quarter company recorded charge million within income expense net devalue net monetary assets venezuela amount represented companys estimate us dollar amount would ultimately collected third quarter company recorded additional exchange losses million aggregate reflecting ongoing effect translating transactions net monetary assets consistent second quarter result deterioration economic conditions venezuela continued declines transactions settled cencoex rate subsequently replaced dipro rate fourth quarter company began using simadi rate vef per us december report venezuelan operations company also revalued remaining net monetary assets simadi rate subsequently replaced dicom rate resulted additional charge fourth quarter million company may also use forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates recorded income expense net effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within comprehensive income oci remains accumulated comprehensive income aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk may four interest rate swaps notional amounts million matured swaps effectively converted companys billion fixedrate notes due variable rate debt december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table table contents millions number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due notes due notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense offset fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion billion respectively one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting policies companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements acquisitions determine whether acquisitions qualify business combinations asset acquisitions company makes certain judgments include assessment inputs processes outputs associated acquired set activities october company adopted new accounting guidance intended clarify whether transactions accounted acquisitions disposals assets businesses company determines substantially fair value gross assets included transaction concentrated single asset group similar assets assets would represent business considered business assets transaction need include input substantive process together significantly contribute ability create outputs prior adoption new guidance company would consider acquisition disposition business inputs well processes applied inputs ability create outputs business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions table contents assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition fair values intangible assets including acquired iprd determined utilizing information available near acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make separate determination useful life asset generally determined period substantial majority cash flows expected generated begin amortization certain companys business acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows subsequent acquisition date reporting period contingent consideration liability remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations company determines transaction accounted acquisition business transaction accounted acquisition assets rather business combination therefore goodwill recorded asset acquisition acquired iprd alternative future use charged expense acquisition date fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd also determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate revenue recognition revenues sales products recognized title risk loss passes customer typically time delivery recognition revenue also requires reasonable assurance collection sales proceeds table contents completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts customers collection accounts receivable expected excess one year provision aggregate indirect customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases directly intermediary wholesaler contracted customer generally purchases product contracted price plus markup wholesaler wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision based expected payments driven patient usage contract performance benefit provider customers company uses historical customer segment mix adjusted known events order estimate expected provision amounts accrued aggregate indirect customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers customers amounts accrued adjustments recorded trends significant events indicate change estimated provision appropriate company continually monitors provision aggregate indirect customer discounts material adjustments estimates associated aggregate indirect customer discount provision summarized information changes aggregate indirect customer discount accrual related us sales follows millions balance january current provision adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market additional generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales percentage us net pharmaceutical sales distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns table contents wholesalers generally provide mentioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million million respectively contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying accruing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated table contents definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pensions postretirement benefit plans net periodic benefit cost pension postretirement benefit plans totaled million million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets changes net periodic benefit cost year year pension plans largely attributable changes discount rate affecting net amortization decrease net periodic benefit cost postretirement benefit plans compared largely attributable changes retiree medical benefits approved company december company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due discount rates companys us pension postretirement benefit plans ranged december compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well actual returns companys plan assets using reference information company develops forward looking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension table contents postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact companys current year net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact mercks current year net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aoci expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized market related value assets ratably fiveyear period also net loss amounts aoci excess certain thresholds amortized net periodic benefit cost average remaining service life employees restructuring costs restructuring costs recorded connection restructuring programs designed streamline companys cost structure result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within materials production costs marketing administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses acquired assigned reporting units company tests goodwill impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit whether sustained declines companys share price additionally company evaluates table contents extent fair value exceeded carrying value reporting unit last date valuation performed company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed acquired intangible assets excluding iprd recorded fair value assigned estimated useful life amortized primarily straight line basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment project company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized within companys operating results judgments made evaluating impairment longlived intangibles materially affect companys results operations impairments investments company reviews investments impairments based determination whether decline market value investment carrying value otherthantemporary company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthan temporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements table contents tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings would practicable determine amount related unrecognized deferred income tax liability recently issued accounting standards may financial accounting standards board fasb issued amended accounting guidance revenue recognition applied contracts customers objective new guidance improve comparability revenue recognition practices across entities provide useful information users financial statements improved disclosure requirements august fasb approved oneyear deferral effective date making guidance effective interim annual periods beginning new standard permits two methods adoption retrospectively prior reporting period presented full retrospective method retrospectively cumulative effect adopting guidance recognized date initial application modified retrospective method company adopt new standard january currently plans use modified retrospective method majority companys business ship bill primary revenue stream merck expect significant differences however companys analysis preliminary subject change merck completed assessment multiple element arrangements certain discount trade promotion programs january fasb issued revised guidance accounting reporting financial instruments new guidance requires equity investments readily determinable fair values currently classified available sale measured fair value changes fair value recognized net income new guidance also simplifies impairment testing equity investments without readily determinable fair values changes certain disclosure requirements guidance effective interim annual periods beginning early adoption permitted company currently assessing impact adoption consolidated financial statements february fasb issued new accounting guidance accounting reporting leases new guidance requires lessees recognize rightofuse asset lease liability recorded balance sheet leases leases meet definition shortterm lease leases classified either operating finance operating leases result straightline expense income statement similar current operating leases finance leases result expense recognized earlier years lease term similar current capital leases new guidance effective interim annual periods beginning early adoption permitted company currently evaluating impact adoption consolidated financial statements june fasb issued amended guidance accounting credit losses financial instruments within scope guidance introduces expected loss model estimating credit losses replacing incurred loss model new guidance also changes impairment model availableforsale debt securities requiring use allowance record estimated credit losses subsequent recoveries new guidance effective interim annual periods beginning earlier application permitted company currently evaluating impact adoption consolidated financial statements august fasb issued guidance classification certain cash receipts payments statement cash flows intended reduce diversity practice guidance effective interim annual periods beginning early adoption permitted guidance applied retrospectively periods presented may applied prospectively retrospective application would impracticable company currently evaluating effect standard consolidated statement cash flows table contents october fasb issued guidance accounting income tax consequences intraentity transfers assets inventory existing guidance recognition current deferred income taxes intraentity asset transfer prohibited asset sold third party new guidance require recognition income tax consequences intraentity transfer asset exception inventory intraentity transfer occurs guidance effective interim annual periods beginning early adoption permitted new guidance applied modified retrospective basis cumulativeeffect adjustment directly retained earnings beginning period adoption company anticipate adoption new guidance material effect consolidated financial statements november fasb issued guidance requiring amounts generally described restricted cash restricted cash equivalents included cash cash equivalents reconciling beginningofperiod endofperiod total amounts shown statement cash flows guidance effective interim annual periods beginning applied using retrospective transition method period presented early adoption permitted company currently evaluating effect standard consolidated statement cash flows january fasb issued guidance provides elimination step goodwill impairment test impairment charges recognized amount recorded amount carrying amount exceeds reporting units fair value certain limitations new guidance effective interim annual periods company anticipate adoption new guidance material effect consolidated financial statements cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forward looking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income comprehensive income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses materials production marketing administrative research development restructuring costs income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income attributable merck co inc comprehensive income loss net taxes net unrealized loss gain derivatives net reclassifications net unrealized loss gain investments net reclassifications benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck co inc accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts excludes accounts receivable classified assets inventories excludes inventories classified assets see note current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc comprehensive loss net tax cash dividends declared common stock per share treasury stock shares purchased astrazeneca option exercise net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive income net tax cash dividends declared common stock per share treasury stock shares purchased changes noncontrolling ownership interests net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net tax cash dividends declared common stock per share treasury stock shares purchased changes noncontrolling ownership interests net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization intangible asset impairment charges charge related settlement worldwide keytruda patent litigation foreign currency devaluation related venezuela net charge related settlement vioxx shareholder class action litigation gain divestiture merck consumer care business gain astrazeneca option exercise loss extinguishment debt equity income affiliates dividends distributions equity method affiliates deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments divestiture merck consumer care business net cash divested dispositions businesses net cash divested proceeds astrazeneca option exercise acquisition cubist pharmaceuticals inc net cash acquired acquisition idenix pharmaceuticals inc net cash acquired acquisitions businesses net cash acquired acquisition bayer ag collaboration rights cash inflows net investment hedges net cash used investing activities cash flows financing activities net change shortterm borrowings payments debt proceeds issuance debt purchases treasury stock dividends paid stockholders dividends paid proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents net decrease increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities sales vaccines major european markets marketed companys sanofi pasteur msd spmsd joint venture termination december beginning merck record vaccine sales european markets previously part joint venture company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients mercks alliances segment primarily includes results companys relationship astrazeneca lp termination relationship june see note october company divested consumer care segment developed manufactured marketed overthecounter foot care sun care products see note summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition company determines assets acquired meet table contents definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost market cost substantial majority domestic pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products well certain inventories produced preparation product launches considered high probability regulatory approval evaluating recoverability inventories produced preparation product launches company considers likelihood revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt equity securities classified availableforsale reported fair value fair values companys investments determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax comprehensive income oci declines fair value equity securities considered otherthan temporary impairment losses charged income expense net company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci realized gains losses debt equity securities included income expense net revenue recognition revenues sales products recognized title risk loss passes customer typically upon delivery recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year accruals chargebacks reflected direct reduction accounts receivable accruals rebates recorded current liabilities accrued balances relative provisions chargebacks rebates included accounts receivable accrued current liabilities million billion respectively december million billion respectively december table contents company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings depreciation expense billion billion billion advertising promotion costs advertising promotion costs expensed incurred company recorded advertising promotion expenses billion billion billion respectively software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development capitalized software costs included property plant equipment amortized beginning software project substantially complete asset ready intended use capitalized software costs associated projects amortized years including companys ongoing multiyear implementation enterprisewide resource planning system million million net accumulated amortization december respectively capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed acquired intangibles acquired intangibles include products product rights tradenames patents recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note company periodically evaluates whether current facts circumstances indicate carrying values acquired intangibles may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference carrying value intangible asset fair value determined based net present value estimated future cash flows acquired inprocess research development acquired inprocess research development iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed fair value less carrying amount impairment loss recognized operating results table contents contingent consideration certain companys business acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probability weighted cash flows subsequent acquisition date reporting period contingent consideration liability remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment research development research development expensed incurred upfront milestone payments due third parties connection research development collaborations prior regulatory approval expensed incurred payments due third parties upon subsequent regulatory approval capitalized amortized shorter remaining license product patent life amounts due collaborative partners related development activities generally reflected reduction research development expenses specific milestone achieved nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include restructuring costs iprd impairment charges periods addition research development expenses include expense income related changes estimated fair value measurement liabilities contingent consideration sharebased compensation company expenses sharebased payments employees requisite service period based grantdate fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income consolidated statement income use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets table contents goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently adopted accounting standards first quarter company adopted accounting guidance issued financial accounting standards board fasb april requires debt issuance costs presented direct deduction carrying amount debt balance sheet opposed presented deferred charge approximately million debt issuance costs reclassified first quarter result adoption new standard prior period amounts recast conform new presentation second quarter company elected early adopt accounting standards update issued fasb march intended simplify accounting reporting employee sharebased payment transactions among provisions new standard requires excess tax benefits deficiencies arise upon vesting exercise sharebased payments recognized income statement opposed previous guidance tax effects recorded paidincapital certain instances aspect new guidance required adopted prospectively resulted recognition million excess tax benefits taxes income arising sharebased payments new guidance also amended presentation certain sharebased payment items statement cash flows cash flows related excess income tax benefits classified operating activity formerly included financing activity company elected adopt aspect new guidance prospectively standard also clarified cash payments made taxing authorities employees behalf shares withheld presented financing activity aspect guidance adopted retrospectively accordingly company reclassified million million payments operating activities financing activities consolidated statement cash flows years ended december respectively conform current presentation company elected continue estimate impact forfeitures determining amount compensation cost recognized period rather account occur fourth quarter company elected early adopt accounting standards update issued fasb january intended clarify definition business objective adding guidance assist entities evaluating whether transactions accounted acquisitions disposals assets businesses substantially fair value gross assets included transaction concentrated single asset group similar assets assets would represent business considered business assets transaction need include input substantive process together significantly contribute ability create outputs prior adoption new guidance acquisition disposition would considered business inputs well processes applied inputs ability create outputs entities permitted apply updated guidance transactions occurring guidance issued long applicable financial statements issued accordingly company elected adopt guidance prospectively october recently issued accounting standards may fasb issued amended accounting guidance revenue recognition applied contracts customers objective new guidance improve comparability revenue recognition practices across entities provide useful information users financial statements improved disclosure requirements august fasb approved oneyear deferral effective date making guidance effective interim annual periods beginning new standard permits two methods adoption retrospectively prior reporting period presented full retrospective method retrospectively cumulative effect adopting guidance recognized date initial application modified retrospective method company adopt new standard january currently plans use modified retrospective method majority companys business ship bill primary revenue stream merck expect significant differences however companys analysis preliminary subject change merck completed assessment multiple element arrangements certain discount trade promotion programs table contents january fasb issued revised guidance accounting reporting financial instruments new guidance requires equity investments readily determinable fair values currently classified available sale measured fair value changes fair value recognized net income new guidance also simplifies impairment testing equity investments without readily determinable fair values changes certain disclosure requirements guidance effective interim annual periods beginning early adoption permitted company currently assessing impact adoption consolidated financial statements february fasb issued new accounting guidance accounting reporting leases new guidance requires lessees recognize rightofuse asset lease liability recorded balance sheet leases leases meet definition shortterm lease leases classified either operating finance operating leases result straightline expense income statement similar current operating leases finance leases result expense recognized earlier years lease term similar current capital leases new guidance effective interim annual periods beginning early adoption permitted company currently evaluating impact adoption consolidated financial statements june fasb issued amended guidance accounting credit losses financial instruments within scope guidance introduces expected loss model estimating credit losses replacing incurred loss model new guidance also changes impairment model availableforsale debt securities requiring use allowance record estimated credit losses subsequent recoveries new guidance effective interim annual periods beginning earlier application permitted company currently evaluating impact adoption consolidated financial statements august fasb issued guidance classification certain cash receipts payments statement cash flows intended reduce diversity practice guidance effective interim annual periods beginning early adoption permitted guidance applied retrospectively periods presented may applied prospectively retrospective application would impracticable company currently evaluating effect standard consolidated statement cash flows october fasb issued guidance accounting income tax consequences intraentity transfers assets inventory existing guidance recognition current deferred income taxes intraentity asset transfer prohibited asset sold third party new guidance require recognition income tax consequences intraentity transfer asset exception inventory intraentity transfer occurs guidance effective interim annual periods beginning early adoption permitted new guidance applied modified retrospective basis cumulativeeffect adjustment directly retained earnings beginning period adoption company anticipate adoption new guidance material effect consolidated financial statements november fasb issued guidance requiring amounts generally described restricted cash restricted cash equivalents included cash cash equivalents reconciling beginningofperiod endofperiod total amounts shown statement cash flows guidance effective interim annual periods beginning applied using retrospective transition method period presented early adoption permitted company currently evaluating effect standard consolidated statement cash flows january fasb issued guidance provides elimination step goodwill impairment test impairment charges recognized amount recorded amount carrying amount exceeds reporting units fair value certain limitations new guidance effective interim annual periods company anticipate adoption new guidance material effect consolidated financial statements table contents acquisitions divestitures research collaborations license agreements company continues acquire businesses establish external alliances research collaborations licensing agreements complement internal research capabilities arrangements often include upfront payments well expense reimbursements payments third party milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development company also reviews marketed products pipeline examine candidates may provide value outlicensing part portfolio assessment process may also divest certain assets pro forma financial information acquired businesses presented historical financial results acquired entity significant compared companys financial results transactions july merck acquired afferent pharmaceuticals afferent privately held pharmaceutical company focused development therapeutic candidates targeting px receptor treatment common poorlymanaged neurogenic conditions afferents lead investigational candidate mk formerly af selective nonnarcotic orallyadministered px antagonist evaluated phase b clinical trial treatment refractory chronic cough well phase clinical trial idiopathic pulmonary fibrosis cough total consideration transferred million included cash paid outstanding afferent shares million well sharebased compensation payments settle equity awards attributable precombination service cash paid transaction costs behalf afferent addition former afferent shareholders eligible receive total additional million contingent upon attainment certain clinical development commercial milestones multiple indications candidates including mk transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date company determined fair value contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream adjusted expected timing payment using appropriate discount rate dependent nature timing milestone payment merck recognized intangible asset inprocess research development iprd million net deferred tax liabilities million net assets million primarily consisting cash acquired excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair value identifiable intangible asset related iprd determined using income approach fair value estimated based upon assets probabilityadjusted future net cash flows reflects stage development project associated probability successful completion net cash flows discounted present value using discount rate actual cash flows likely different assumed also july merck wholly owned subsidiary healthcare services solutions llc acquired majority ownership interest staywell company llc staywell portfolio company vestar capital partners vestar staywell health engagement company helps clients engage educate people improve health business results terms transaction merck paid million majority ownership interest additionally merck provided staywell million intercompany loan pay preexisting thirdparty debt merck option buy vestar option require merck buy vestars remaining ownership interest fair value beginning three years acquisition date transaction accounted acquisition business merck recognized intangible assets million deferred tax liabilities million net liabilities million noncontrolling interest million excess consideration transferred fair value net assets acquired million recorded goodwill largely attributable anticipated synergies expected arise acquisition goodwill allocated healthcare services segment deductible tax purposes intangible assets recognized primarily relate customer relationships amortized year useful life medical information solutions content amortized fiveyear useful life additionally july merck announced executed agreement acquire controlling interest valle sa valle leading privately held producer animal health products brazil valle extensive portfolio products spanning parasiticides antiinfectives vaccines include products livestock horses companion animals terms agreement merck acquire approximately shares valle approximately million based exchange rates time announcement agreement subject regulatory review certain closing conditions table contents june merck moderna therapeutics moderna entered strategic collaboration license agreement develop commercialize novel messenger rna mrnabased personalized cancer vaccines development program entail multiple studies several types cancer include evaluation mrnabased personalized cancer vaccines combination mercks keytruda pursuant terms agreement merck made upfront cash payment moderna million recorded research development expenses following human proof concept studies merck right elect make additional payment moderna merck exercises right two companies equally share cost profits worldwide collaboration development personalized cancer vaccines moderna right elect copromote personalized cancer vaccines united states agreement entails exclusivity around combinations keytruda moderna merck ability combine mrnabased personalized cancer vaccines nonpd agents january merck acquired iomet pharma ltd iomet privately held ukbased drug discovery company focused development innovative medicines treatment cancer particular emphasis fields cancer immunotherapy cancer metabolism acquisition provides merck iomets preclinical pipeline ido indoleaminedioxygenase tdo tryptophandioxygenase dualacting idotdo inhibitors transaction accounted acquisition business total purchase consideration transaction included cash payment million future additional milestone payments million contingent upon certain clinical regulatory milestones achieved company determined fair value contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream adjusted expected timing payment utilizing discount rate merck recognized intangible assets iprd million net deferred tax assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value also using discount rate actual cash flows likely different assumed transactions december company divested remaining ophthalmics portfolio international markets mundipharma ophthalmology products limited merck received consideration approximately million recognized gain million recorded income expense net july merck acquired ccam biotherapeutics ltd ccam privately held biopharmaceutical company focused discovery development novel cancer immunotherapies total purchase consideration transaction included upfront payment million cash future additional payments million associated attainment certain clinical development regulatory commercial milestones transaction accounted acquisition business merck recognized intangible asset iprd million related cm monoclonal antibody well liability contingent consideration million goodwill million net assets million result unfavorable efficacy data company determined would discontinue development pipeline program accordingly company recorded iprd impairment charge million related cm reversed related liability contingent consideration fair value million time program discontinuation iprd impairment charge income related reduction liability contingent consideration recorded research development expenses also july merck allergan plc allergan entered agreement pursuant allergan acquired exclusive worldwide rights mk mk mercks investigational small molecule oral calcitonin generelated peptide cgrp receptor antagonists developed treatment prevention migraine terms agreement allergan acquired rights upfront payments million million paid august upon closing transaction remaining million paid april company recorded gain million within income expense net related transaction allergan fully responsible development cgrp programs well manufacturing commercialization upon approval launch products agreement merck entitled receive potential development commercial milestone payments royalties tiered doubledigit rates based commercialization table contents programs merck recognized gains million within income expense net resulting payments allergan achievement research development milestones february merck ngm biopharmaceuticals inc ngm privately held biotechnology company entered multiyear collaboration research discover develop commercialize novel biologic therapies across wide range therapeutic areas terms agreement merck made upfront payment ngm million included research development expenses purchased equity stake ngm million merck committed million fund ngms efforts initial fiveyear term collaboration potential additional funding certain conditions met prior merck initiating phase study licensed program ngm may elect either receive milestone royalty payments certain cases cofund development participate global cost revenue share arrangement agreement also provides ngm option participate copromotion cofunded program united states merck option extend research agreement two additional twoyear terms january merck acquired cubist pharmaceuticals inc cubist leader development therapies treat serious infections caused broad range bacteria total consideration transferred billion included cash paid outstanding cubist shares billion well sharebased compensation payments settle equity awards attributable precombination service cash paid transaction costs behalf cubist sharebased compensation payments settle nonvested equity awards attributable postcombination service recognized transaction expense addition company assumed outstanding convertible debt cubist fair value approximately billion acquisition date merck redeemed debt february transaction accounted acquisition business estimated fair value assets acquired liabilities assumed cubist follows estimated fair value january cash cash equivalents accounts receivable inventories current assets property plant equipment identifiable intangible assets products product rights year weightedaverage useful life iprd noncurrent assets current liabilities deferred income tax liabilities longterm debt noncurrent liabilities total identifiable net assets goodwill consideration transferred included current liabilities noncurrent liabilities contingent consideration million million respectively goodwill recognized largely attributable anticipated synergies expected arise acquisition allocated pharmaceutical segment goodwill deductible tax purposes estimated fair values identifiable intangible assets related currently marketed products determined using income approach fair value estimated based market participant expectations assets discounted projected net cash flows companys estimates projected net cash flows considered historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles extent timing potential new product introductions companys competitors life table contents assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing discount rate actual cash flows likely different assumed company recorded fair value incomplete research project surotomycin mk time acquisition reached technological feasibility alternative future use second quarter company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge see note connection cubist acquisition liabilities recorded potential future consideration contingent upon achievement future salesbased milestones fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows changes inputs could result different fair value measurement transaction closed january accordingly results operations acquired business included companys results operations beginning date company incurred million transaction costs directly related acquisition cubist including sharebased compensation costs severance costs legal advisory fees reflected marketing administrative expenses following unaudited supplemental pro forma data presents consolidated information acquisition cubist completed january years ended december sales net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders unaudited supplemental pro forma data reflects historical information merck cubist adjusted include additional amortization expense based fair value assets acquired additional interest expense would incurred borrowings used fund acquisition transaction costs associated acquisition related tax effects adjustments pro forma data considered indicative results would occurred acquisition consummated january indicative future results transactions december merck acquired oncoethix privately held biotechnology company specializing oncology drug development total purchase consideration transaction included upfront cash payment million future additional milestone payments million contingent upon certain clinical regulatory milestones achieved transaction accounted acquisition business merck recognized intangible asset iprd million related mk formerly otx investigational novel oral bet bromodomain inhibitor well liability contingent consideration million net assets million result unfavorable efficacy data company determined would discontinue development mk accordingly company recorded iprd impairment charge million related mk reversed related liability contingent consideration fair value million time program discontinuation iprd impairment charge income related reduction liability contingent consideration recorded research development expenses october company completed sale merck consumer care mcc business bayer ag bayer billion billion net cash divested less customary closing adjustments well certain contingent amounts held back payable upon manufacturing site transfer canada regulatory approval table contents korea terms agreement bayer acquired mercks existing overthecounter business including global trademark prescription rights claritin afrin company recognized pretax gain sale mcc billion recorded income expense net also october company entered worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulators including bayers adempas riociguat approved treat pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension two companies equally share costs profits collaboration implement joint development commercialization strategy collaboration also includes clinical development bayers vericiguat phase trials worsening heart failure well optin rights earlystage sgc compounds development bayer merck turn made available earlystage sgc compounds similar terms return broad collaboration rights merck made upfront payment bayer billion potential additional milestone payments billion upon achievement agreedupon sales goals agreement bayer lead commercialization adempas americas merck lead commercialization rest world vericiguat potential optin products bayer lead rest world merck lead americas products candidates included agreement companies share development costs profits sales right copromote territories lead company determined mercks payment access bayers compounds constituted acquisition asset billion consideration paid merck million fair value related adempas capitalized intangible asset subject amortization estimated useful life years remaining million fair value related vericiguat compound clinical development expensed within research development expenses fair values adempas vericiguat determined using income approach probabilityadjusted future net cash flows discounted present value using discount rate adempas vericiguat second quarter company determined probable adempas sales would exceed threshold triggering million milestone payment merck bayer accordingly second quarter company recorded million liability corresponding intangible asset also recognized million cumulative amortization expense within materials production costs remaining intangible asset june million amortized thenremaining estimated useful life years supported projected future cash flows subject impairment testing remaining potential future milestone payments million yet accrued deemed company probable time august merck completed acquisition idenix pharmaceuticals inc idenix approximately billion cash billion net cash acquired idenix biopharmaceutical company engaged discovery development medicines treatment human viral diseases whose primary focus development nextgeneration oral antiviral therapeutics treat hepatitis c virus hcv infection transaction accounted acquisition business merck recognized intangible asset iprd billion related mk formerly idx uprifosbuvir well net deferred tax liabilities million net liabilities million uprifosbuvir nucleotide prodrug clinical development evaluated treatment hcv infection excess consideration transferred fair value net assets acquired billion recorded goodwill allocated pharmaceutical segment deductible tax purposes fair value identifiable intangible asset related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value using discount rate company recorded billion iprd impairment charge related uprifosbuvir resulted recent changes product profile taken together changes companys expectations pricing market opportunity see note may merck entered agreement sell certain ophthalmic products santen pharmaceutical co ltd santen japan markets europe asia pacific agreement provided upfront payments santen additional payments based defined sales milestones santen also purchase supply ophthalmology products covered agreement two fiveyear period transaction closed markets july remaining markets october company received million upfront payments santen net certain adjustments recognized gains million transactions included income expense net table contents march merck sold sirna therapeutics inc sirna subsidiary alnylam pharmaceuticals inc alnylam consideration million shares alnylam common stock merck eligible receive future payments associated achievement certain regulatory commercial milestones well royalties future sales merck recorded gain million income expense net related transaction excess mercks tax basis investment sirna value received resulted approximate million tax benefit recorded january merck sold us marketing rights saphris antipsychotic indicated treatment schizophrenia bipolar disorder adults forest laboratories inc forest terms agreement forest made upfront payments million recorded sales make additional payments merck based defined sales milestones addition part transaction merck agreed supply product forest subsequently acquired allergan patent expiry remicadesimponi subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company marketing rights products throughout europe russia turkey remicade lost market exclusivity major european markets february company longer market exclusivity marketing territories company continues market exclusivity simponi marketing territories profits derived mercks distribution two products countries equally divided merck jj restructuring company incurs substantial costs restructuring program activities related mercks productivity cost reduction initiatives well connection integration certain acquired businesses company commenced actions global restructuring programs designed streamline cost structure actions programs include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company also continues reduce global real estate footprint improve efficiency manufacturing supply network nonfacility related restructuring actions programs substantially complete remaining activities primarily relate ongoing facility rationalizations company recorded total pretax costs billion billion billion related restructuring program activities since inception programs december merck recorded total pretax accumulated costs approximately billion eliminated approximately positions comprised employee separations well elimination contractors vacant positions company expects substantially complete remaining actions programs end incur approximately million additional pretax costs company estimates approximately twothirds cumulative pretax costs result cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring program activities type cost separation accelerated costs depreciation total year ended december materials production marketing administrative research development restructuring costs year ended december materials production marketing administrative research development restructuring costs year ended december materials production marketing administrative research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated positions eliminated restructuring program activities approximately position eliminations comprised actual headcount reductions elimination contractors vacant positions accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future undiscounted cash flows sufficient recover respective book values merck recorded accelerated depreciation site assets anticipated site closure dates particularly related manufacturing locations may continue adjusted reflect changes resulting regulatory factors activity includes million million million respectively asset abandonment shutdown related costs additionally activity includes certain employeerelated costs associated pension postretirement benefit plans see note share based compensation activity also reflects net pretax losses resulting sales facilities related assets million million million table contents following table summarizes charges spending relating restructuring program activities separation accelerated costs depreciation total restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december remaining cash outlays expected substantially completed end financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted foreign currency denominated sales portion forecasted sales hedged based assessments cost benefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges effective portion unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized hedge relationship highly effective hedge ineffectiveness de minimis derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes table contents company manages operating activities net asset positions local level order mitigate effect exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statement cash flows monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year company may also use forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates recorded income expense net effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within oci remains aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci included cumulative translation adjustment pretax gains million million million eurodenominated notes interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk may four interest rate swaps notional amounts million matured swaps effectively converted companys billion fixedrate notes due variable rate debt december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due notes due notes due table contents interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense offset fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows presented table fair value derivatives gross basis segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative derivative us dollar us dollar balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments interest rate swap contracts assets interest rate swap contracts accrued current liabilities interest rate swap contracts noncurrent liabilities foreign exchange contracts current assets foreign exchange contracts assets foreign exchange contracts accrued current liabilities foreign exchange contracts noncurrent liabilities derivatives designated hedging instruments foreign exchange contracts current assets foreign exchange contracts assets foreign exchange contracts accrued current liabilities foreign exchange contracts noncurrent liabilities table contents noted company records derivatives gross basis consolidated balance sheet company master netting agreements several financial institution counterparties see concentrations credit risk following table provides information companys derivative positions subject master netting arrangements presented net basis allowing right offset counterparty cash collateral exchanged per master agreements related credit support annexes december asset liability asset liability gross amounts recognized consolidated balance sheet gross amount subject offset master netting arrangements offset consolidated balance sheet cash collateral received posted net amounts table provides information location pretax gain loss amounts derivatives designated fair value hedging relationship ii designated foreign currency cash flow hedging relationship iii designated foreign currency net investment hedging relationship iv designated hedging relationship years ended december derivatives designated fair value hedging relationship interest rate swap contracts amount loss gain recognized income expense net derivatives amount gain loss recognized income expense net hedged item derivatives designated foreign currency cash flow hedging relationships foreign exchange contracts amount gain reclassified aoci sales amount gain recognized oci derivatives derivatives designated foreign currency net investment hedging relationships foreign exchange contracts amount gain recognized income expense net derivatives amount loss gain recognized oci derivatives derivatives designated hedging relationship foreign exchange contracts amount loss gain recognized income expense net derivatives amount gain loss recognized sales million million million ineffectiveness hedge respectively ineffectiveness hedge represents amount excluded hedge effectiveness testing derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates december company estimates million pretax net unrealized gains derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity table contents investments debt equity securities information investments debt equity securities december follows gross unrealized gross unrealized fair amortized fair amortized value cost gains losses value cost gains losses corporate notes bonds commercial paper us government agency securities assetbacked securities mortgagebacked securities foreign government bonds equity securities availableforsale debt securities included shortterm investments totaled billion december remaining debt securities billion mature within five years december debt securities pledged collateral fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets liabilities whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well assets liabilities determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets investments corporate notes bonds commercial paper us government agency securities assetbacked securities mortgagebacked securities foreign government bonds equity securities assets us government agency securities corporate notes bonds mortgagebacked securities assetbacked securities foreign government bonds equity securities derivative assets purchased currency options forward exchange contracts interest rate swaps total assets liabilities liabilities contingent consideration derivative liabilities forward exchange contracts interest rate swaps written currency options total liabilities primarily assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily auto loan credit card student loan receivables weightedaverage lives primarily years less mortgagebacked securities represent aaarated securities issued unconditionally guaranteed payment principal interest us government agencies increase investments included assets reflects certain assets previously restricted retiree benefits became available fund certain health welfare benefits see note fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant transfers level level december cash cash equivalents billion included billion cash equivalents considered level fair value hierarchy table contents contingent consideration summarized information changes liabilities contingent consideration follows fair value january changes fair value additions payments fair value december recorded research development expenses materials production costs changes fair value largely attributable reversal liabilities related programs obtained connection acquisitions ccam oncoethix smartcells see note additions contingent consideration relate termination spmsd joint venture see note acquisitions iomet afferent see note additions contingent consideration relate acquisitions cubist ccam see note payments contingent consideration relate first commercial sale zerbaxa european union relate first commercial sale zerbaxa united states fair value measurements companys financial instruments cash cash equivalents receivables payables reflected balance sheet carrying value approximates fair value due shortterm nature estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using recent observable market prices would considered level fair value hierarchy concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines majority companys accounts receivable arise product sales united states europe primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor economic conditions including volatility associated international sovereign economies associated impacts financial markets business taking consideration global economic conditions ongoing sovereign debt issues certain european countries december companys total net accounts receivable outstanding one year approximately million company expect writeoffs adjustments accounts receivable would material adverse effect financial position liquidity results operations companys customers largest accounts receivable balances mckesson corporation amerisourcebergen corporation cardinal health inc zuellig pharma ltd asia pacific aah pharmaceuticals ltd uk represented aggregate approximately total accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty table contents december company received cash collateral million million respectively various counterparties obligation return collateral recorded accrued current liabilities company advanced cash collateral counterparties december inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost increase lifo costs recognized inventories assets inventories valued lifo method comprised approximately billion billion inventories december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year addition amounts included million million december respectively inventories produced preparation product launches goodwill intangibles following table summarizes goodwill activity segment pharmaceutical total balance january acquisitions divestitures impairments balance december acquisitions impairments balance december includes cumulative translation adjustments goodwill balances certain adjustments accumulated goodwill impairment losses december million million respectively additions goodwill pharmaceutical segment resulted primarily acquisitions afferent iomet see note well termination spmsd joint venture treated stepacquisition accounting purposes see note addition goodwill within nonreportable segments relates acquisition staywell part healthcare services segment see note additions goodwill pharmaceutical segment resulted primarily acquisition cubist reductions resulted divestiture companys remaining ophthalmics business international markets see note impairments goodwill within nonreportable segments relate certain businesses within healthcare services segment table contents intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights iprd tradenames acquired intangibles include products product rights tradenames patents recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives increase intangible assets products product rights primarily relates recognition intangible assets connection termination spmsd joint venture see note companys significant acquired intangibles related marketed products included product product rights december include zerbaxa billion zetia billion sivextro million vytorin million implanonnexplanon million dificid million gardasilgardasil million nuvaring million nasonex million company recognized intangible asset related adempas result formation collaboration bayer see note carrying value million december reflected table company recorded impairment charges related marketed products intangibles million million billion respectively within material production costs company lowered cash flow projections zontivity product reduction thrombotic cardiovascular events patients history myocardial infarction peripheral arterial disease following several business decisions reduced sales expectations zontivity united states europe company utilized market participant assumptions considered several different scenarios determine fair value intangible asset related zontivity compared related carrying value resulted impairment charge million also company wroteoff million capitalized connection inlicensed products grastek ragwitek allergy immunotherapy tablets business reasons company determined return licensor charges primarily relate impairment customer relationship tradename intangibles certain businesses within healthcare services segment amount recorded million related pegintron million related victrelis million related rebetol products treatment chronic hcv infection developments competitive hcv treatment market led market share losses greater company predicted causing changes cash flow projections pegintron victrelis rebetol indicated intangible asset values recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair values intangible assets related pegintron victrelis rebetol compared related carrying values resulted impairment charges noted iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized iprd accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life asset begin amortization million million million respectively iprd reclassified products product rights upon receipt marketing approval major market company recorded billion iprd impairment charges within research development expenses amount billion relates clinical development program uprifosbuvir nucleotide prodrug clinical development evaluated treatment hcv company determined recent changes product profile well changes mercks expectations pricing market opportunity taken together constituted triggering event required company evaluate uprifosbuvir intangible asset impairment utilizing market participant assumptions considering different scenarios company concluded table contents best estimate current fair value intangible asset related uprifosbuvir million resulting recognition pretax impairment charge noted iprd impairment charges also include charges million million related discontinuation programs obtained connection acquisitions ccam oncoethix respectively resulting unfavorable efficacy data additional million relates programs obtained connection smartcells acquisition following decision terminate lead compound due lack efficacy pursue backup compound reduced projected future cash flows iprd impairment charges also include million related inlicensed program house dust mite allergies business reasons returned licensor remaining iprd impairment charges primarily relate deprioritized pipeline programs deemed alternative use period including million impairment charge investigational candidate contraception discontinuation delay certain clinical development programs resulted reduction related liabilities contingent consideration see note company recorded million iprd impairment charges million related surotomycin clinical development program company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge noted company recorded million iprd impairment charges primarily result changes cash flow assumptions certain compounds obtained connection companys joint venture supera farma laboratorios sa supera well discontinuation certain animal health programs iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates company may recognize additional noncash impairment charges future related marketed products pipeline programs charges could material aggregate amortization expense primarily recorded within materials production costs billion billion billion estimated aggregate amortization expense next five years follows billion billion billion billion billion joint ventures equity method affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates including spmsd termination december certain investment funds well azlp termination companys relationship azlp june equity income affiliates million million million included income expense net see note investments affiliates accounted using equity method totaled million december million december amounts reported assets amounts due joint ventures included current assets million december million december sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture spmsd market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales billion million billion december merck sanofi pasteur sanofi terminated spmsd ended joint vaccines operations europe terms termination merck acquired sanofis interest spmsd exchange consideration million comprised cash well future royalties net sales merck products december company determined fair value million date table contents termination company accounted transaction step acquisition required merck remeasure ownership interest previously accounted equity method investment fair value acquisition date merck turn sold sanofi intellectual property rights held spmsd exchange consideration million comprised cash future royalties net sales sanofi products december company determined fair value million date termination excluded arrangement potential future sales vaxelis jointly developed investigational pediatric hexavalent combination vaccine approved european commission february european marketing rights vaxelis transferred separate equallyowned joint venture sanofi merck mcm net impact termination spmsd joint venture follows products product rights year useful life accounts receivable income taxes payable deferred income tax liabilities net goodwill net assets acquired consideration payable sanofi net derecognition mercks previously held equity investment spmsd increase net assets mercks share restructuring costs related termination net gain termination spmsd joint venture goodwill allocated pharmaceutical segment deductible tax purposes recorded income expense net estimated fair values identifiable intangible assets related products product rights determined using income approach fair value estimated based market participant expectations assets projected net cash flows projected net cash flows discounted present value utilizing discount rate actual cash flows likely different assumed amount recorded products product rights million relates gardasilgardasil fair value liabilities contingent consideration related mercks future royalty payments sanofi million reflected consideration payable sanofi net table determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows riskadjusted discount rate used present value cash flows changes inputs could result different fair value measurement based existing accounting policy election merck recorded million estimated fair value contingent future royalties received sanofi sale sanofi products rather recognize amounts future periods sales occur royalties earned company incurred million transaction costs related termination spmsd included marketing administrative expenses pro forma financial information transaction presented results significant compared companys financial results astrazeneca lp merck entered agreement astra ab astra develop market astra products royaltybearing license mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states merck astra completed restructuring ownership operations joint venture whereby merck acquired astras interest ami renamed kbi inc kbi contributed kbis table contents operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights connection restructuring ami merck assumed billion par value preferred stock dividend rate per annum carried kbi included noncontrolling interests merck earned revenue based sales kbi products revenue million primarily relating sales nexium well prilosec addition merck earned certain partnership returns azlp million recorded equity income affiliates june astrazeneca exercised option purchase mercks interest kbi million cash amount million reflected estimate fair value mercks interest nexium prilosec portion exercise price subject trueup based actual sales closing june deferred recognized income million million million respectively income expense net contingency eliminated sales occurred deferred income amount fully amortized first quarter company began recognizing income corresponding receivable amounts due merck astrazeneca based sales performance nexium prilosec subject trueup june company recognized million income included income expense net remaining exercise price million primarily represents multiple ten times mercks average annual profit allocation partnership three years prior exercise merck recognized million gain within income expense net result astrazenecas option exercise companys remaining interest azlp redeemed accordingly company also recognized noncash gain approximately million within income expense net resulting retirement billion kbi preferred stock elimination companys billion investment azlp million reduction goodwill transaction resulted net tax benefit million primarily reflecting reversal deferred taxes azlp investment balance result astrazeneca exercising option july company longer records equity income azlp supply sales azlp terminated summarized financial information azlp follows year ended december sales materials production costs expense net income taxes includes results june termination date mercks partnership returns azlp generally contractually determined noted based percentage income azlp respect mercks limited partnership interest loans payable longterm debt commitments loans payable december included million notes due million longdated notes subject repayment option holder loans payable december included billion notes due million shortterm foreign borrowings million longdated notes subject repayment option holders weightedaverage interest rate commercial paper borrowings years ended december respectively table contents longterm debt december consisted notes due notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due eurodenominated notes due notes due floatingrate borrowing due notes due notes due notes due floatingrate notes due notes due eurodenominated notes due eurodenominated notes due eurodenominated notes due notes due notes due notes due debentures due debentures due debentures due floatingrate notes due presented table included million million december respectively borrowings variable rates resulted effective interest rates zero respectively also included foreign borrowings million december varying rates exception debentures due notes listed table redeemable whole part mercks option time varying redemption prices november company issued billion principal amount senior unsecured notes consisting million principal amount notes due million principal amount notes due company intends use net proceeds offering billion general corporate purposes including without limitation repayment outstanding commercial paper borrowings indebtedness upcoming maturities october company issued billion principal amount senior unsecured notes net proceeds offering billion used part repay debt validly tendered connection tender offers launched company certain outstanding notes debentures company paid billion aggregate consideration applicable purchase price together accrued interest redeem billion principal table contents amount debt november merck redeemed additional billion principal amount senior unsecured notes company recorded pretax loss million connection transactions effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date certain companys borrowings require merck comply financial covenants including requirement total debt capitalization ratio defined applicable agreements exceed december company compliance covenants aggregate maturities longterm debt next five years follows million billion billion billion billion june company terminated existing credit facility entered new billion fiveyear credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility rental expense operating leases net sublease income million million million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including environmental matters opinion company unlikely resolution matters material companys financial position results operations cash flows given nature litigation discussed complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities effective august vioxx litigation product liability lawsuits previously disclosed merck defendant number putative class action lawsuits alleging economic injury result purchase vioxx one settled settlement merck agreed pay million resolve properly documented claims submitted class members approved attorneys fees expenses approved settlement notice costs certain administrative expenses claims table contents review process completed company paying approximately amount attorneys fees paid yet determined merck also defendant lawsuit together abovereferenced lawsuits vioxx product liability lawsuits brought attorney general utah lawsuit pending utah state court utah alleges merck misrepresented safety vioxx seeks damages penalties utah false claims act trial date set merck recently reached agreements attorneys general alaska montana settle state consumer protection act cases company million million respectively result alaskas action dismissed prejudice september montanas action dismissed prejudice october shareholder lawsuits previously disclosed addition vioxx product liability lawsuits various putative class actions individual lawsuits filed merck certain former employees alleging defendants violated federal securities laws making alleged material misstatements omissions respect cardiovascular safety vioxx vioxx securities lawsuits vioxx securities lawsuits coordinated multidistrict litigation us district court district new jersey judge stanley r chesler previously disclosed merck reached resolution vioxx securities class action reserve recorded merck created settlement fund million settlement class fund agreed pay additional amount approved attorneys fees expenses million feeexpense fund june court approved settlement awarded attorneys fees expenses amount million remaining amount feeexpense fund added settlement class fund company paid total settlement amount escrow april available funds certain insurance policies mercks net cash payment settlement fees approximately million settlement covers claims relating vioxx settlement class members purchased merck securities may october settlement admission wrongdoing part settlement agreement defendants continue deny allegations addition merck reached resolution referenced individual securities lawsuits filed foreign domestic institutional investors also consolidated vioxx securities lawsuits insurance result previously disclosed insurance arbitration companys insurers paid insurance proceeds approximately million connection settlement class action company also directors officers insurance coverage applicable vioxx securities lawsuits remaining stated upper limits approximately million company received disputes insurers availability companys directors officers insurance coverage claims amounts actually recovered directors officers policies discussed paragraph may less stated upper limits international lawsuits previously disclosed addition lawsuits discussed merck named defendant litigation relating vioxx brazil europe collectively vioxx international lawsuits litigation jurisdictions generally procedural stages merck expects litigation may continue number years reserves company immaterial reserve respect certain vioxx product liability lawsuits company established liability reserves believes meritorious defenses remaining vioxx product liability lawsuits vioxx international lawsuits defend product liability litigation fosamax previously disclosed merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases filed pending table contents merck either federal state court approximately actions plaintiffs allege among things suffered osteonecrosis jaw onj generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax addition plaintiffs approximately actions generally allege sustained femur fractures andor bone injuries femur fractures association use fosamax cases alleging onj andor jaw related injuries august judicial panel multidistrict litigation jpml ordered certain fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax onj mdl coordinated pretrial proceedings december merck reached agreement principle plaintiffs steering committee psc fosamax onj mdl resolve pending onj cases appeal fosamax onj mdl state courts aggregate amount million merck psc subsequently formalized terms agreement master settlement agreement onj master settlement agreement executed april included plaintiffs july merck elected proceed onj master settlement agreement reduced funding level million since participation level approximately merck fully funded onj master settlement agreement escrow agent agreement making settlement payments qualifying plaintiffs onj master settlement agreement effect cases alleging femur fractures discussed discovery currently ongoing approximately remaining onj cases pending various federal state courts company intends defend lawsuits cases alleging femur fractures march merck submitted motion transfer jpml seeking federal cases alleging femur fractures consolidated one multidistrict litigation coordinated pretrial proceedings motion transfer granted may federal cases involving allegations femur fracture transferred multidistrict litigation district new jersey femur fracture mdl bellwether case tried date femur fracture mdl glynn v merck jury returned verdict mercks favor addition june femur fracture mdl court granted mercks motion judgment matter law glynn case held plaintiffs failure warn claim preempted federal law august femur fracture mdl court entered order requiring plaintiffs femur fracture mdl show cause cases asserting claims femur fracture injury took place prior september dismissed based courts preemption decision glynn case pursuant show cause order march femur fracture mdl court dismissed prejudice approximately cases preemption grounds plaintiffs approximately cases appealing decision us court appeals third circuit third circuit femur fracture mdl court since dismissed without prejudice another approximately cases pending plaintiffs appeal preemption ruling third circuit june third circuit heard oral argument plaintiffs appeal preemption ruling parties awaiting decision addition june femur fracture mdl court granted merck summary judgment gaynor v merck case found mercks updates january fosamax label regarding atypical femur fractures adequate matter law merck adequately communicated changes plaintiffs gaynor appealed courts decision third circuit august merck filed motion requesting court enter order requiring plaintiffs femur fracture mdl claim fosamax label inadequate proximate cause alleged injuries show cause cases dismissed based courts preemption decision ruling gaynor case november court granted mercks motion entered requested show cause order december seven cases pending femur fracture mdl excluding cases dismissed prejudice preemption grounds pending appeal cases dismissed without prejudice also pending aforementioned appeal table contents december approximately cases alleging femur fractures filed new jersey state court pending judge jessica mayer middlesex county parties selected initial group cases reviewed fact discovery two additional groups cases reviewed fact discovery selected november march respectively group cases reviewed fact discovery selected merck july merck continued select additional cases reviewed fact discovery december approximately cases alleging femur fractures filed pending california state court petition filed seeking coordinate femur fracture cases filed california state court single judge orange county california petition granted judge thierry colaw currently presiding coordinated proceedings march court directed group discovery pool cases reviewed fact discovery subsequently scheduled galper v merck case plaintiffs selected first trial galper trial began february jury returned verdict mercks favor april plaintiff appealed verdict california appellate court oral argument plaintiffs appeal galper held november parties awaiting decision next femur fracture trial california scheduled begin april stayed plaintiffs request new trial date set additionally five femur fracture cases pending state courts discovery ongoing femur fracture mdl state courts femur fracture cases pending company intends defend lawsuits januviajanumet previously disclosed merck defendant product liability lawsuits united states involving januvia andor janumet december approximately product user claims served merck alleging generally use januvia andor janumet caused development pancreatic cancer injuries complaints filed several different state federal courts claims filed consolidated multidistrict litigation proceeding us district court southern district california called incretinbased therapies products liability litigation mdl mdl includes federal lawsuits alleging pancreatic cancer due use following medicines januvia janumet byetta victoza latter two products manufactured pharmaceutical companies majority claims filed mdl filed superior court california county los angeles california state court december eight product users claims pending merck state courts california state court november mdl california state court separate opinions granted summary judgment defendants grounds preemption approximately served product user claims rulings resulted dismissal approximately product user claims plaintiffs appealing mdl california state court preemption rulings addition claims noted company agreed december toll statute limitations approximately additional claims company intends continue defending lawsuits propeciaproscar previously disclosed merck defendant product liability lawsuits united states involving propecia andor proscar december approximately lawsuits filed plaintiffs allege experienced persistent sexual side effects following cessation treatment propecia andor proscar approximately plaintiffs also allege propecia proscar caused cause prostate cancer testicular cancer male breast cancer lawsuits filed various federal courts state court new jersey federal lawsuits consolidated pretrial purposes federal multidistrict litigation judge brian cogan eastern district new york matters pending state court new jersey consolidated judge jessica mayer middlesex county addition one matter pending state court california one matter pending state court new york one matter pending state court ohio company intends defend lawsuits table contents governmental proceedings previously disclosed company received civil investigative demand us attorneys office southern district new york requests information relating companys contracts services payments pharmacy benefit managers respect maxalt levitra january present company cooperating investigation previously disclosed company received subpoena office inspector general us department health human services behalf us attorneys office district maryland civil division us department justice doj requests information relating companys marketing singulair dulera inhalation aerosol certain marketing activities january present company cooperating investigation previously disclosed company received civil investigative demand us attorneys office eastern district pennsylvania requested information relating companys contracting pricing dulera inhalation aerosol certain pharmacy benefit managers medicare part plans company cooperated investigation august company learned underlying qui tam complaint unsealed voluntarily dismissed prejudice relator without prejudice government doj informed company matter inactive current investigation previously disclosed company received letters doj sec seek information activities number countries reference foreign corrupt practices act company cooperated agencies requests believes inquiry part broader review pharmaceutical industry practices foreign countries previously disclosed company advised doj based information received closed inquiry matter relates company company also recently advised sec closed inquiry matter relates company previously disclosed companys subsidiaries china received may continue receive inquiries regarding operations various chinese governmental agencies inquiries may related matters involving multinational pharmaceutical companies well chinese entities business companies companys policy cooperate authorities provide responses appropriate time time company receives inquiries subject preliminary investigation activities competition authorities various markets outside united states certain inquiries activities may lead commencement formal proceedings proceedings determined adversely company monetary fines andor remedial undertakings may required commercial litigation kdur antitrust litigation previously disclosed june january scheringplough corporation scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relating generic versions scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upshersmith filed abbreviated new drug applications andas following commencement administrative proceeding us federal trade commission alleging anticompetitive effects settlements resolved schering ploughs favor putative class nonclass action suits filed behalf direct indirect purchasers kdur scheringplough upshersmith lederle consolidated multidistrict litigation us district court district new jersey suits claimed violations federal state antitrust laws well state statutory common law causes action sought unspecified damages april indirect purchasers voluntarily dismissed case february district court denied companys motion summary judgment relating direct purchasers claims concerning settlement upshersmith granted companys motion summary judgment relating direct purchasers claims concerning settlement lederle anticipation trial parties filed motions exclude certain expert opinions evidence defendants filed motion summary judgment table contents february merck upshersmith reached settlement principle class direct purchasers optouts class merck contribute approximately million aggregate towards overall settlement formal settlement agreements class optouts yet executed settlement class subject approval district court sales force litigation previously disclosed may ms kelli smith filed complaint company us district court district new jersey behalf putative class female sales representatives putative subclass female sales representatives children claiming discriminatory policies practices selection promotion advancement b disparate pay c differential treatment hostile work environment e retaliation federal state discrimination laws plaintiffs sought granted leave file amended complaint january plaintiffs filed amended complaint adding four additional named plaintiffs october court denied companys motion dismiss strike class claims premature september plaintiffs filed additional motions including motion conditional certification equal pay act motion amend pleadings seeking add erisa constructive discharge claims company subsidiary named defendant motion equitable relief merck filed papers opposition motions april court granted plaintiffs motion conditional certification denied plaintiffs motions extend liability period equal pay act claims back june result liability period date back april earliest april magistrate judge granted plaintiffs request amend complaint add following company subsidiary corporate defendant ii erisa claim iii individual constructive discharge claim one named plaintiffs approximately individuals optedin action optin period closed qui tam litigation previously disclosed june us district court eastern district pennsylvania unsealed complaint filed company federal false claims act two former employees alleging among things company defrauded us government falsifying data connection clinical study conducted mumps component companys mmr ii vaccine complaint alleges fraud took place us government right participate take prosecution lawsuit notified court declined exercise right two former employees pursuing lawsuit without involvement us government addition previously disclosed two putative class action lawsuits behalf direct purchasers mmr ii vaccine charge company misrepresented efficacy mmr ii vaccine violation federal antitrust laws various state consumer protection laws pending eastern district pennsylvania september court denied mercks motion dismiss false claims act suit granted part denied part motion dismiss thenpending antitrust suit result false claims act suit antitrust suits proceeded discovery company intends defend lawsuits merck kgaa litigation january protect longestablished brand rights united states company filed lawsuit merck kgaa darmstadt germany kgaa operating emd group united states alleging improperly uses name merck united states kgaa filed suit company france united kingdom uk germany switzerland mexico india alleging breach parties coexistence agreement unfair competition andor trademark infringement december paris court first instance issued judgment finding certain activities company directed towards france constitute trademark infringement unfair competition activities found infringe company kgaa appealed decision appeal scheduled heard may january uk high court issued judgment finding company breached coexistence agreement infringed kgaas trademark rights result certain activities directed towards uk based use word merck promotional information activity noted uk decision finding based companys use sign merck connection sale products material pharmaceutical business transacted uk company kgaa appealed decision appeal scheduled heard june table contents patent litigation time time generic manufacturers pharmaceutical products file andas us food drug administration fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies certain products company products marketed via agreements companies currently involved patent infringement litigation united states include cancidas invanz nasonex noxafil nuvaring similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products respect products acquired acquisitions potentially significant intangible asset impairment charges cancidas february patent infringement lawsuit filed united states xellia pharmaceuticals aps xellia respect xellias application fda seeking prepatent expiry approval market generic version cancidas june district court found xellia infringed companys patent ordered xellias application approved patent expires september including pediatric exclusivity xellia appealed decision appeal heard march may parties reached settlement whereby xellia launch generic version august earlier certain conditions august patent infringement lawsuit filed united states fresenius kabi usa llc fresenius respect freseniuss application fda seeking prepatent expiry approval market generic version cancidas december parties reached settlement whereby fresenius launch generic version august earlier certain conditions invanz july patent infringement lawsuit filed united states hospira respect hospiras application fda seeking prepatent expiry approval market generic version invanz trial matter held april october district court ruled patent valid infringed august patent infringement lawsuit filed united states savior lifetec corporation savior respect saviors application fda seeking prepatent expiry approval market generic version invanz lawsuit automatically stays fda approval saviors application november adverse court decision whichever may occur earlier nasonex july patent infringement lawsuit filed united states teva pharmaceuticals usa inc teva pharma respect teva pharmas application fda seeking prepatent expiry approval market generic version nasonex trial matter held june november district court ruled patent valid infringed company appealed decision march patent infringement lawsuit filed united states amneal pharmaceuticals llc amneal respect amneals application fda seeking prepatent expiry approval market generic version nasonex trial matter held june january district court ruled patent valid infringed company appealed decision previous decision issued june held merck patent teva pharma amneal lawsuits covering mometasone furoate monohydrate valid infringed apotex corps proposed product april patent infringement lawsuit filed apotex inc apotex corp apotex respect apotexs nowlaunched product company believes differs generic version previous lawsuit noxafil august company filed lawsuit actavis laboratories fl inc actavis united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil lawsuit automatically stays fda approval actaviss application december adverse court decision whichever may occur earlier trial matter currently scheduled begin july march company filed lawsuit roxane laboratories inc roxane united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil lawsuit automatically stays fda approval roxanes application august adverse court decision whichever may occur earlier february company filed lawsuit par sterile products llc par pharmaceutical inc par pharmaceutical companies inc par pharmaceutical holdings inc collectively par united states respect companys application fda seeking pre table contents patent expiry approval sell generic version noxafil october parties reached settlement whereby par launch generic version january earlier certain conditions nuvaring december company filed lawsuit subsidiary allergan plc united states respect companys application fda seeking prepatent expiry approval sell generic version nuvaring trial matter held january august district court ruled patent invalid company appealed decision september company filed lawsuit teva pharma united states respect companys application fda seeking prepatent expiry approval sell generic version nuvaring based ruling allergan plc matter district court dismissed companys lawsuit december company appealed decision company involved ongoing litigation canada apotex concerning companys patents related lovastatin alendronate norfloxacin litigation either settled concluded consequence conclusion litigation company recorded net gain million included income expense net see note antipd antibody patent oppositions litigation previously disclosed ono pharmaceutical co ono european patent ep broadly claims use antipd antibody companys immunotherapy keytruda treatment cancer ono previously licensed commercial rights antipd antibody bristol myers squibb bms certain markets bms ono also european patent ep granted broadly claimed antipd antibodies could include keytruda previously disclosed company bms ono engaged worldwide litigation including united states validity infringement patent patent equivalents january company announced entered settlement license agreement bms ono resolving worldwide patent infringement litigation related use antipd antibody treatment cancer keytruda settlement license agreement company made onetime payment million recorded expense companys financial results bms pay royalties worldwide sales keytruda nonexclusive license market keytruda market approved global net sales keytruda company pay royalties follows net sales occurring january including december net sales occurring january including december parties also agreed dismiss claims worldwide relevant legal proceedings october pdl biopharma pdl filed lawsuit united states company alleging manufacture keytruda infringed us patent patent expired december patent claims platform technology used creation manufacture recombinant antibodies pdl seeking damages preexpiry infringement patent july company filed declaratory judgment action united states genentech city hope seeking ruling us patent cabilly iii patent claims platform technology used creation manufacture recombinant antibodies invalid keytruda bezlotoxumab infringe cabilly iii patent july company also filed petition uspto inter partes review ipr certain claims us patent cabilly ii patent claims platform technology used creation manufacture recombinant antibodies also owned genentech city hope invalid december uspto denied petition allowed company join ipr filed previously another party gilead patent litigation opposition august gilead sciences inc gilead filed lawsuit us district court northern district california seeking declaration two company patents invalid infringed sale two sofosbuvir containing products solvadi harvoni company filed counterclaim sale table contents products infringe two patents sought reasonable royalty past present future sales products march conclusion jury trial patents found invalid infringed jury awarded company million royalty sales products december conclusion jury trial court held bench trial equitable defenses raised gilead june court found gilead determined merck could collect jury award patents unenforceable respect gilead company appealed courts decision gilead also asked court overturn jurys decision validity court held hearing gileads motion august court subsequently rejected gileads request company pay net legal fees damages royalties receives ionis pharmaceuticals inc company idenix pharmaceuticals inc subsidiary pending litigation gilead united states uk norway canada germany france australia based different patent estates would also infringed gileads sales two products gilead opposed european patent epo trial united states held december jury returned verdict company awarding damages billion company currently briefing posttrial motions including issues enhanced damages future royalties gilead briefing posttrial motions judgment matter law uk australia canada company initially unsuccessful cases currently appeal norway patent held invalid appeal filed epo opposition division revoked european patent company appealed decision cases france germany stayed pending final decision epo litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial position results operations cash flows either individually aggregate legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate environmental matters previously disclosed mercks facilities oss netherlands inspected province brabant province pursuant dutch hazards major accidents decree sites environmental permits province issued penalties alleged violations regulations governing preventing managing accidents hazardous substances government also issued fine alleged environmental violations one oss facilities together totaled thousand company subsequently advised criminal investigation initiated based upon certain issues formed basis administrative enforcement action province company intends defend enforcement action may result investigation may environmental protection agency conducted air compliance evaluation companys pharmaceutical manufacturing facility elkton virginia result investigation company table contents recently issued notice noncompliance show cause notification relating certain federally enforceable requirements applicable elkton facility company attempting resolve alleged violations way settlement defend settlement reached company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying accruing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year equity merck certificate incorporation authorizes shares common stock shares preferred stock capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january purchases treasury stock issuances balance december issuances primarily reflect activity sharebased compensation plans sharebased compensation plans company sharebased compensation plans company grants restricted stock units rsus performance share units psus certain management level employees company also issues rsus employees certain companys equity method investees addition employees nonemployee directors may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders table contents december million shares collectively authorized future grants companys sharebased compensation plans awards settled primarily treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest one third year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus psus dividends declared vesting period payable employees upon vesting psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period generally three years subject terms applicable awards total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term years value outstanding january granted exercised forfeited outstanding december exercisable december table contents additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries addition company provides medical benefits principally eligible us retirees dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost pension postretirement benefit plans consisted following components pension benefits us international postretirement benefits years ended december service cost interest cost expected return plan assets net amortization termination benefits curtailments settlements net periodic benefit credit cost changes net periodic benefit credit cost year year pension plans largely attributable changes discount rate affecting net amortization decrease net periodic benefit cost postretirement benefit plans compared largely attributable changes retiree medical benefits approved company december connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments recorded pension table contents postretirement benefit plans settlements recorded certain us international pension plans reflected table obligations funded status summarized information changes plan assets benefit obligations funded status amounts recorded december follows pension benefits postretirement us international benefits fair value plan assets january actual return plan assets company contributions effects exchange rate changes benefits paid settlements assets longer restricted payment postretirement benefits fair value plan assets december benefit obligation january service cost interest cost actuarial losses gains benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities noncurrent liabilities result certain allowable administrative actions occurred june million plan assets previously restricted payment postretirement benefits became available fund certain health welfare benefits actuarial losses actuarial gains primarily reflect changes discount rates decline postretirement benefit obligations resulting plan amendments primarily reflects changes mercks retiree medical benefits approved company december changes provide beginning merck provide access retiree health insurance coverage supplements governmentsponsored medicare private insurance marketplace december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans table contents information related funded status selected pension plans december follows us international pension plans projected benefit obligation excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligation excess plan assets accumulated benefit obligation fair value plan assets plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately respectively companys pension investments categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total us pension plans assets cash cash equivalents investment funds developed markets equities emerging markets equities equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments net assets fair value hierarchy investments measured nav practical expedient plan assets fair value international pension plans assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations corporate obligations fixed income obligations real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts net assets fair value hierarchy investments measured nav practical expedient plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy fair value amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december plans level investments real estate funds generally valued market appraisals underlying investments funds plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total us pension plans balance january actual return plan assets relating assets still held december relating assets sold year purchases sales net balance december international pension plans balance january actual return plan assets relating assets still held december purchases sales net transfers level balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities net assets fair value hierarchy investments measured nav practical expedient plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy fair value amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation table contents plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions expected contributions approximately million us pension plans approximately million international pension plans approximately million postretirement benefit plans expected benefit payments expected benefit payments follows international pension postretirement us pension benefits benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net periodic benefit cost average remaining service life employees following amounts reflected components oci pension plans postretirement us international benefit plans years ended december net loss gain arising period prior service cost credit arising period net loss amortization included benefit cost prior service credit cost amortization included benefit cost estimated net loss gain prior service cost credit amounts amortized aoci net periodic benefit cost million million respectively pension plans million million respectively relates us pension plans million million respectively postretirement benefit plans table contents actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining us pension postretirement benefit plan international pension plan information follows us pension postretirement benefit plans international pension plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined plan basis developing expected rate return within plan longterm historical returns data considered well actual returns plan assets capital markets experience using reference information longterm return expectations asset category weighted average expected return plans target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects one percentage point increase decrease effect total service interest cost components effect benefit obligation savings plans company also maintains defined contribution savings plans united states company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net income expense net consisted years ended december interest income interest expense exchange losses equity income affiliates net higher exchange losses compared related primarily venezuelan bolvar second quarter upon evaluation evolving economic conditions venezuela volatility country combined decline transactions settled official cencoex rate vef bolvar fuertes per us dollar company determined unlikely outstanding net monetary assets would settled cencoex rate accordingly second quarter company recorded charge million devalue net monetary assets venezuela amount represented companys estimate us dollar amount would ultimately collected third quarter company recorded additional exchange losses million aggregate reflecting ongoing effect translating transactions net monetary assets consistent second quarter fourth quarter result deterioration economic conditions venezuela continued declines transactions settled official rate company began using simadi rate report venezuelan operations company also revalued remaining net monetary assets simadi rate subsequently replaced dicom rate resulted additional charge fourth quarter million since january venezuela designated hyperinflationary result local foreign operations remeasured us dollars impact recorded results operations decline equity income affiliates compared driven primarily lower equity income certain research investment funds net presented table includes charge million settle worldwide patent litigation related keytruda see note gain million related settlement patent litigation see note gains million resulting receipt milestone payments licensed migraine clinical development programs see note million income related astrazenecas option exercise see note net includes million net charge related settlement vioxx shareholder class action litigation see note expense million contribution investments equity securities merck foundation partially offset million gain sale certain migraine clinical development programs see note million gain divestiture mercks remaining ophthalmics business international markets see note recognition million deferred income related astrazenecas option exercise net includes billion gain divestiture mcc see note gain million related astrazenecas option exercise million gain divestiture certain ophthalmic products several international markets see note gain million related sale sirna see note recognition million deferred income related astrazenecas option exercise partially offset million loss extinguishment debt see note million goodwill impairment charge related companys joint venture supera interest paid million million million table contents taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising foreign earnings unremitted foreign earnings tax settlements astrazeneca option exercise sale sirna therapeutics inc impact purchase accounting adjustments including amortization foreign currency devaluation related venezuela state taxes restructuring us health care reform legislation divestiture merck consumer care includes tax effect contingency reserves research credits miscellaneous items foreign earnings tax rate differentials tax rate reconciliation primarily reflect impacts operations jurisdictions different tax rates united states particularly ireland switzerland well singapore puerto rico operate tax incentive grants earnings indefinitely reinvested thereby yielding favorable impact effective tax rate compared us statutory rate foreign earnings tax rate differentials include impact intangible asset impairment charges amortization purchase accounting adjustments restructuring costs items presented separately represent significant separately disclosed pretax cost charge substantial portion items relates jurisdictions lower tax rates united states therefore impact recording expense items lower tax rate jurisdictions unfavorable impact effective tax rate compared us statutory rate companys effective tax rate reflects impact protecting americans tax hikes act signed law december extending research credit permanently controlled foreign corporation lookthrough provisions five years companys effective tax rate reflects impact tax increase prevention act signed law december extending research credit controlled foreign corporation lookthrough provisions one year income taxes consisted years ended december domestic foreign table contents taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation unremitted foreign earnings pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized assets deferred income taxes company net operating loss nol carryforwards several jurisdictions december million deferred taxes nol carryforwards relate foreign jurisdictions none individually significant valuation allowances million established foreign nol carryforwards foreign deferred tax assets addition company million deferred tax assets relating various us tax credit carryforwards nol carryforwards expected fully utilized prior expiry income taxes paid billion billion billion respectively income taxes paid reflects approximately billion taxes paid divestiture mcc tax benefits relating stock option exercises million million million table contents reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations balance december amounts reflect settlements irs discussed company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease billion next months result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures however one item currently discussion internal revenue service irs relating examination company concluded position sustained upon audit however item result unfavorable outcome settlement could material adverse impact companys financial position liquidity results operations expenses interest penalties associated uncertain tax positions amounted million million million amounts reflect beneficial impacts various tax settlements including discussed liabilities accrued interest penalties million million december respectively irs currently conducting examinations companys tax returns years well although irss examination companys federal tax returns concluded prior one issue relating refund claim remained open issue resolved company received refund approximately million exceeded receivable previously recorded company resulting tax benefit million addition various state foreign tax examinations progress significant tax jurisdictions us state foreign companys income tax returns open examination period december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings would practicable determine amount related unrecognized deferred income tax liability addition company subsidiaries operating puerto rico singapore tax incentive grants begin expire table contents earnings per share calculations earnings per share shares millions follows years ended december net income attributable merck co inc average common shares outstanding common shares issuable average common shares outstanding assuming dilution basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive comprehensive income loss changes aoci component follows employee cumulative accumulated benefit translation comprehensive derivatives investments plans adjustment income loss balance january net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes relates foreign currency cash flow hedges reclassified aoci sales represents net realized gains losses sales availableforsale investments reclassified aoci income expense net includes net amortization prior service cost actuarial gains losses included net periodic benefit cost see note includes pension plan net loss billion billion december respectively postretirement benefit plan net loss million million december respectively well pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table contents segment reporting companys operations principally managed products basis comprised four operating segments pharmaceutical animal health healthcare services alliances animal health healthcare services alliances segments material separate reporting pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccine sales made us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles sales vaccines major european markets marketed companys spmsd joint venture termination december see note company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers company made changes composition animal health segment resulted inclusion certain revenues costs previously included nonsegment revenues profits prior periods recast reflect changes comparable basis companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients mercks alliances segment primarily includes results companys relationship azlp termination relationship june see note october company divested consumer care segment developed manufactured marketed overthecounter foot care sun care products see note table contents sales companys products follows years ended december primary care womens health cardiovascular zetia vytorin diabetes januvia janumet general medicine womens health nuvaring implanonnexplanon dulera follistim aq hospital specialty hepatitis zepatier hiv isentress hospital acute care cubicin noxafil invanz cancidas bridion primaxin immunology remicade simponi oncology keytruda emend temodar diversified brands respiratory singulair nasonex cozaarhyzaar arcoxia fosamax zocor vaccines gardasilgardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales cubicin represent sales subsequent cubist acquisition date sales cubicin reflect sales japan pursuant previously existing licensing agreement amounts reflect sales vaccines sold major european markets companys joint venture spmsd results reflected equity income affiliates included income expense net amounts however reflect supply sales spmsd december merck sanofi terminated spmsd joint venture see note pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments animal health healthcare services alliances well consumer care divestiture october see note alliances segment includes revenue companys relationship azlp termination june see note primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales also includes approximately million million respectively connection sale marketing rights certain products table contents consolidated revenues geographic area derived follows years ended december united states europe middle east africa asia pacific japan latin america reconciliation total segment profits consolidated income taxes follows years ended december segment profits pharmaceutical segment segments total segment profits profits unallocated interest income interest expense equity income affiliates depreciation amortization research development amortization purchase accounting adjustments restructuring costs gain sale certain migraine clinical development programs charge related settlement worldwide keytruda patent litigation gain divestiture certain ophthalmic products foreign currency devaluation related venezuela net charge related settlement vioxx shareholder class action litigation gain divestiture merck consumer care gain astrazeneca option exercise loss extinguishment debt unallocated net segment profits comprised segment sales less standard costs certain operating expenses directly incurred segments internal management reporting presented chief operating decision maker merck allocate materials production costs standard costs majority research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits addition costs related restructuring activities well amortization purchase accounting adjustments allocated segments profits primarily comprised miscellaneous corporate profits well operating profits related thirdparty manufacturing sales unallocated net includes expenses corporate manufacturing cost centers goodwill intangible asset impairment charges gains losses sales businesses expense income related changes estimated fair value contingent consideration miscellaneous income expense items table contents equity income affiliates depreciation amortization included segment profits follows pharmaceutical total year ended december included segment profits equity income affiliates depreciation amortization year ended december included segment profits equity income affiliates depreciation amortization year ended december included segment profits equity income affiliates depreciation amortization property plant equipment net geographic area located follows december united states europe middle east africa asia pacific latin america japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors shareholders merck co inc opinion accompanying consolidated balance sheets related consolidated statements income comprehensive income equity cash flows present fairly material respects financial position merck co inc subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso company 's management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included management 's report item responsibility express opinions financial statements company 's internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp florham park new jersey february table contents b supplementary data selected quarterly financial data contained condensed interim financial data table condensed interim financial data unaudited millions except per share amounts th q rd q nd q st q sales materials production marketing administrative research development restructuring costs income expense net loss income taxes net loss income attributable merck co inc basic loss earnings per common share attributable merck co inc common shareholders loss earnings per common share assuming dilution attributable merck co inc common shareholders sales materials production marketing administrative research development restructuring costs income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders amounts include charge settle worldwide patent litigation related keytruda see note amounts reflect net charge related settlement vioxx shareholder class action litigation see note foreign exchange losses related venezuela see note gain sale companys remaining ophthalmics business international markets see note amounts include gain sale certain migraine clinical development programs see note amounts include foreign exchange losses related devaluation companys net monetary assets venezuela see note amounts reflect acquisition divestiturerelated costs see note impact restructuring actions see note table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices annually employees company required complete code conduct training includes financial stewardship training reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december table contents inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein kenneth c frazier robert davis chairman president executive vice president global services chief financial chief executive officer officer item b information none table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion proposal election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting shareholders held may company code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer controller code conduct available companys website wwwmerckcomaboutcodeofconductpdf company intends disclose future amendments certain provisions code conduct waivers code conduct granted executive officers directors website within four business days following date amendment waiver every merck employee responsible adhering business practices accordance law ethical principles reflect highest standards corporate individual behavior printed copy sent without charge shareholder requests writing chief ethics compliance officer merck co inc galloping hill road kenilworth nj required information identification audit committee audit committee financial expert incorporated reference discussion heading board meetings committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards table option exercises stock vested table pension benefits table nonqualified deferred compensation table potential payments upon termination change control including discussion subheadings separation change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting shareholders held may required information headings compensation benefits committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may table contents item security ownership certain beneficial owners management related stockholder matters information respect security ownership certain beneficial owners management incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans merck us savings plan number number securities remaining securities available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck sharp dohme incentive stock plans merck co inc nonemployee directors stock option plans merck co inc scheringplough stock incentive plans excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans also excludes shares phantom stock deferred msd employee deferral program shares phantom stock deferred merck co inc plan deferred payment directors compensation item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion proposal ratification appointment independent registered public accounting firm beginning caption preapproval policy services independent registered public accounting firm fees services provided independent registered public accounting firm companys proxy statement annual meeting shareholders held may table contents part iv item